Therapeutic targeting of tumor cell plasticity in colorectal cancer by Schmidt, Eva Marina
 Aus dem Pathologischen Institut  
der Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. med. Thomas Kirchner 
 
 
 
Therapeutic targeting of tumor cell 
plasticity in colorectal cancer 
 
 
Dissertation zum Erwerb des 
Doktorgrades der Naturwissenschaften (Dr. rer. nat.) 
an der Medizinischen Fakultät  
der Ludwig-Maximilians-Universität München 
 
 
 
vorgelegt von 
 
Eva Marina Schmidt 
 
aus München 
 
2018  
  
 
Gedruckt mit der Genehmigung der Medizinischen Fakultät 
der Ludwig-Maximilians-Universität München 
 
 
Betreuer:    Prof. Dr. rer. nat. Andreas Jung 
Zweitgutachter:   Prof. Dr. rer. nat. Roland Kappler 
 
Dekan:    Prof. Dr. med. dent. Reinhard Hickel 
 
Tag der mündlichen Prüfung:  19.12.2018 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meiner Familie
EIDESSTATTLICHE VERSICHERUNG 
   III 
 
EIDESSTATTLICHE VERSICHERUNG 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem 
Thema 
„ Therapeutic targeting of tumor cell plasticity in colorectal cancer “ 
selbständig verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient 
und alle Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen 
sind, als solche kenntlich gemacht und nach ihrer Herkunft unter Bezeichnung der 
Fundstelle einzeln nachgewiesen habe. 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder 
in ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen 
Grades eingereicht wurde. 
 
München, 20.06.2018 
 
Eva Marina Schmidt 
 
PUBLICATIONS 
   IV 
 
PUBLICATIONS 
Parts of this thesis have been published in: 
 Schmidt, E. M., Lamprecht, S., Blaj, C., Schaaf, C., Krebs, S., Blum, H., 
Hermeking, H., Jung, A., Kirchner, T. & Horst, D. Targeting tumor cell plasticity by 
combined inhibition of NOTCH and MAPK signaling in colon cancer. J. Exp. Med. 
215, 1693-1708 (2018). 
In addition, I contributed to the following publications, which are not further described 
in this thesis: 
 Lamprecht, S. *, Kaller, M. *, Schmidt, E. M., Blaj, C., Schiergens, T. S., 
Engel, J., Jung, A., Hermeking, H., Grünewald, T. G. P., Kirchner, T. & Horst, D. 
PBX3 is part of an EMT regulatory network and indicates poor outcome in 
colorectal cancer. Clin. Cancer Res. 24, 1974-1986 (2018). * Authors contributed 
equally to this work. 
 
 Lamprecht, S., Schmidt, E. M., Blaj, C., Hermeking, H., Jung, A., Kirchner, T. & 
Horst, D. Multicolor lineage tracing reveals clonal architecture and dynamics in 
colon cancer. Nat. Commun. 8, 1-9 (2017). 
 
 Blaj, C., Schmidt, E. M., Lamprecht, S., Hermeking, H., Jung, A., Kirchner, T. & 
Horst, D. Oncogenic effects of high MAPK activity in colorectal cancer mark 
progenitor cells and persist irrespective of RAS mutations. Cancer Res. 77, 
1763-1774 (2017). 
  
PUBLICATIONS 
   V 
 
 Blaj, C., Bringmann, A., Schmidt, E. M., Urbischek, M., Lamprecht, S., 
Fröhlich, T., Arnold, G. J., Krebs, S., Blum, H., Hermeking, H., Jung, A., 
Kirchner, T. & Horst, D. ADNP is a therapeutically inducible repressor of WNT 
signaling in colorectal cancer. Clin. Cancer Res. 23, 2769-2780 (2017). 
 
 Woischke, C.*, Blaj, C.*, Schmidt, E. M.*, Lamprecht, S., Engel, J., 
Hermeking, H., Kirchner, T. & Horst, D. CYB5R1 links epithelial-mesenchymal 
transition and poor prognosis in colorectal cancer. Oncotarget 7, 31350-31360 
(2016). * Authors contributed equally to this work. 
CONTENTS 
   VI 
 
CONTENTS 
EIDESSTATTLICHE VERSICHERUNG ........................................................... III 
PUBLICATIONS ............................................................................................... IV 
1 INTRODUCTION ......................................................................................... 1 
1.1 Colorectal cancer ....................................................................................................... 1 
1.1.1 Epidemiology ................................................................................................... 1 
1.1.2 Genetic background and hallmarks of cancer ................................................... 1 
1.2 Signaling-pathway alterations in colorectal cancer ..................................................... 4 
1.2.1 The WNT pathway ........................................................................................... 4 
1.2.2 The Mitogen-activated protein kinase pathway ................................................. 4 
1.2.3 The transforming growth factor-β-signaling pathway and the p53 protein ......... 6 
1.2.4 The NOTCH pathway ....................................................................................... 7 
1.3 Epithelial-mesenchymal transition ............................................................................ 10 
1.4 Colorectal cancer stem cells .................................................................................... 13 
1.5 Treatment of colorectal cancer ................................................................................. 15 
1.5.1 Surgery and chemotherapy ............................................................................ 15 
1.5.2 Targeted therapy against oncogenic signaling pathways ................................ 15 
2 AIMS OF THE STUDY .............................................................................. 17 
3 MATERIALS .............................................................................................. 18 
3.1 Chemicals and reagents .......................................................................................... 18 
3.2 Enzymes .................................................................................................................. 20 
3.3 Kits ........................................................................................................................... 21 
3.4 Oligonucleotides and vectors ................................................................................... 22 
3.4.1 Oligonucleotides ............................................................................................. 22 
3.4.2 Vectors ........................................................................................................... 22 
CONTENTS 
   VII 
 
3.5 Antibodies ................................................................................................................ 23 
3.5.1 Primary antibodies ......................................................................................... 23 
3.5.2 Secondary antibodies ..................................................................................... 24 
3.6 Buffers and solutions................................................................................................ 24 
3.7 Laboratory equipment .............................................................................................. 27 
4 METHODS ................................................................................................ 28 
4.1 Cloning of pLenti Trace ............................................................................................ 28 
4.2 Bacterial cell culture ................................................................................................. 28 
4.3 Mammalian cell culture ............................................................................................ 29 
4.3.1 Propagation of human cell lines and patient-derived colon cancers ................ 29 
4.3.2 Lentiviral transductions ................................................................................... 29 
4.4 Tumor xenografts and in vivo treatments ................................................................. 30 
4.5 Immunoblotting ........................................................................................................ 31 
4.6 Histological staining procedures ............................................................................... 32 
4.6.1 Immunohistochemistry ................................................................................... 32 
4.6.2 Immunofluorescence ...................................................................................... 33 
4.7 Gene expression analysis and GSEA ...................................................................... 33 
4.8 Clinical samples ....................................................................................................... 34 
4.9 Statistical analysis .................................................................................................... 35 
5 RESULTS .................................................................................................. 36 
5.1 High NOTCH activity indicates a distinct tumor cell subpopulation in colon cancer .. 36 
5.2 MAPK and NOTCH activity are associated with colon cancer progression ............... 40 
5.3 Colon cancers evade MAPK- or NOTCH-targeted therapy by shifting their    
 phenotype ................................................................................................................ 45 
5.4 MAPK and NOTCH have opposite effects on epithelial differentiation in                
 colon cancer ............................................................................................................ 49 
5.5 Plasticity of MAPK and NOTCH signaling in colon cancer cells ................................ 54 
CONTENTS 
   VIII 
 
5.6 Treatment effects of MAPK and NOTCH repression in colon cancer ........................ 59 
6 DISCUSSION ............................................................................................ 64 
SUMMARY ...................................................................................................... 70 
ZUSAMMENFASSUNG ................................................................................... 71 
ABBREVIATIONS ............................................................................................ 72 
REFERENCES ................................................................................................ 75 
ACKNOWLEDGMENT..................................................................................... 87 
 
 
INTRODUCTION 
   1 
 
1 INTRODUCTION 
1.1 Colorectal cancer 
1.1.1 Epidemiology 
Cancer is one of the leading public health problems worldwide with 17.5 million new 
cases recorded in 2015 1,2. Among those, colorectal cancer (CRC) is the third most 
common cancer in males and the second most frequent in females 2, and is a major 
cause of cancer mortality 3,4. The risk of developing CRC is associated with a number 
of dietary and lifestyle factors, including alcohol consumption, smoking, diet rich in 
red meat, and reduced physical activity 3,5. CRC-caused mortality is decreasing due 
to progress in CRC screenings, enhanced awareness in diet and lifestyle, as well as 
improvements in cancer therapy 5,6. However, the number of CRC-related deaths with 
835,000 in 2015 remains a social burden 2. Hence, further research is needed to 
develop new concepts for therapy in order to increase survival rates of patients with 
CRC.  
1.1.2 Genetic background and hallmarks of cancer 
The development of CRC is a multistep process involving mutational changes in the 
genome 7–9. For transformation of colon epithelial cells into malignant cancer cells, at 
least four to five mutations in so called driver genes are required 8, which mediate a 
selective growth advantage 10. Driver gene mutations typically either activate 
oncogenes or cause loss of function of tumor suppressor genes, both contributing to 
tumor formation 9. The main genetic alterations and their occurrence during colorectal 
tumorigenesis are described in the adenoma-carcinoma sequence model, which was 
proposed by Fearon and Vogelstein 8 (Figure 1). 
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Figure 1. Adenoma-carcinoma sequence model. 
Representative H&E stained sections of normal colon epithelium, small and large adenoma, and carcinoma. Driver 
gene mutations acquired during carcinogenesis and corresponding pathway alterations are indicated below. Figure 
was adapted from references 
8,10
. 
The first driver gene mutations often arise in Adenomatous polyposis coli (APC) 7,10,11, 
leading to transformation of normal mucosa into small adenomas 7 (Figure 1). APC 
mutations are observed in approximately 70-80 % of sporadic colorectal adenomas 
and carcinomas 4, and are crucial for tumor initiation 7. For malignant transformation, 
further mutations in other driver genes are required 7,10,11. The KRAS gene is mutated 
in about 50 % of adenomas larger than 1 cm 4,12, and mutated KRAS contributes to 
the expansion of preexisting adenomas 10,13 (Figure 1). Also, loss of heterozygosity 
(LOH) on chromosome 18q is found in more than 70 % of CRC 4,12. Due to 18q LOH, 
mutations in the SMAD4 gene may emerge, which are associated with advanced 
stages of malignant transformation 14,15 (Figure 1). Furthermore, mutations in the 
TP53 gene may arise, which are mainly detectable in carcinomas with an estimated 
frequency of 60 % 11,12 (Figure 1). These four driver gene mutations are highly 
frequent in CRC and often occur within the adenoma-carcinoma sequence 8,12.  
Accumulated driver gene mutations synergistically induce the development of 
essential functional capabilities, transmitting selective growth advantages to mutated 
epithelial cells and thus foster colorectal tumor development and cancer 
progression 9,16. The acquired capabilities, such as sustained proliferation and 
evasion of apoptosis, are not only relevant to CRC but are common features of most 
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types of human cancer and were referred to as the hallmarks of cancer by Hanahan 
and Weinberg in 2000 9 (Figure 2). 
 
Figure 2. The hallmarks of cancer. 
Functional capabilities of human cancer acquired during tumor development. Figure was adapted from reference 
16
.  
Additional capabilities of cancer cells, such as the induction of angiogenesis, 
replicative immortality, and the activation of invasion and metastasis further 
contribute to carcinogenesis 16 (Figure 2). These hallmarks of cancer are often 
influenced by the aberrant activation or inactivation of distinct signaling pathways, 
which is frequently caused by mutations in the mentioned driver genes APC, KRAS, 
SMAD4 and TP53 9.  
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1.2 Signaling-pathway alterations in colorectal cancer 
1.2.1 The WNT pathway 
In this context, the WNT pathway appears to assume a central role in tumor initiation 
of CRCs 17,18. Aberrant WNT signaling is induced by APC mutations causing the 
functional loss of the tumor suppressor protein APC. Under physiological conditions, 
APC serves as a negative regulator of β-catenin, which is part of the canonical WNT 
signaling pathway 19. Upon APC loss, β-catenin accumulates in the nucleus and 
forms a stable complex with the transcription factor TCF4. This induces constitutive 
transcriptional activation of WNT target genes 17,20 (Figure 1). Intestinal epithelial cells 
with persistent WNT-signaling activity then are shifted into a proliferative phenotype 
with simultaneous blockage of terminal differentiation 9,20,21. Thus, APC-mutated 
intestinal epithelial cells may selectively expand, which is the basis for adenoma 
formation 18,21. Despite the presence of APC mutations within all tumors cells of a 
CRC, WNT signaling is heterogeneously activated within most of these tumors 22,23. 
Specifically, active WNT signaling is frequently detectable in tumor cells at the 
infiltrative tumor edge 22,24. On the contrary, colon cancer cells located more centrally 
within the tumor have a comparatively low activity for this pathway 22,24,25.  
1.2.2 The Mitogen-activated protein kinase pathway 
Further pathway alterations often occur in the mitogen-activated protein kinase 
(MAPK)-signaling pathway, which seems to be associated with tumor progression of 
CRCs 26. The MAPK signaling pathway is a key regulator of normal cell proliferation, 
differentiation, survival, and motility 27,28. Pathway activity is mediated by MAPKs, a 
family of evolutionarily conserved kinases that transmit signals from extracellular 
stimuli into specific intracellular responses 27,29. This signaling pathway involves 
different MAPK cascades, among which the RAS-RAF-MEK-ERK cascade plays a 
crucial role in CRC 30–32 (Figure 3).  
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Figure 3. The RAS-RAF-MEK-ERK cascade. 
Upon growth factor binding, the receptor is activated and adaptor proteins are recruited to the intracellular domains. 
Adaptor proteins shift RAS proteins to the guanosine triphosphate (GTP) bound state for activation. RAS-GTP 
activates RAF (MAPKKK), which in turn phosphorylates and activates MEK (MAPKK). MEK further catalyzes the 
phosphorylation of ERK (MAPK), which translocates to the nucleus to phosphorylate transcription factors and effector 
proteins, and thus contributes to target-gene transcription. Figure was adapted from reference 
33
. 
The RAS-RAF-MEK-ERK cascade is activated by growth factor binding to tyrosine 
kinase receptors, e.g. the epidermal growth factor receptor (EGFR) located at the cell 
membrane 31,34 (Figure 3). Upon receptor activation, the intracellular domains of the 
receptor are autophosphorylated and subsequently the adaptor proteins GRB2 and 
SOS are recruited 28,34. These proteins then activate RAS proteins such as KRAS by 
shifting inactive RAS bound to guanosine diphosphate (GDP) to its active guanosine 
triphosphate (GTP)-bound state 35,36. RAS-GTP stimulates RAF, a MAPK kinase 
kinase, which in turn phosphorylates and thereby activates MEK (MAPK kinase) 
(Figure 3). MEK further catalyzes the phosphorylation of the MAPK extracellular 
signal-regulated kinase (ERK) 33,34,36. Following this, activated ERKs translocate to 
the nucleus phosphorylating and activating various transcription factors and effector 
proteins 31,33,34 (Figure 3). For instance, the transcription factor JUN is phosphorylated 
by ERK and subsequently complexes with the protein FOS to form the activator 
protein 1 (AP1) transcription factor 35,37. The gene FOSL1, as part of the AP1 
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transcription factor family, encodes FOS-related antigen 1 (FRA1), which is an 
indicator for MAPK pathway activity 38. 
In CRC, mutations in the driver gene KRAS lead to the activation of the 
MAPK-signaling pathway 4,11 (Figure 1). In mutated cancer cells, KRAS accumulates 
in the active GTP-bound state leading to increased activity of its downstream 
signaling cascade 36,39,40. Findings suggest that this aberrant MAPK activity facilitates 
sustained proliferation of mutated colon cancer cells 16,41 and thereby may contribute 
to the formation of large villous adenomas 10 (Figure 1). Similar to WNT pathway 
activity, MAPK signaling is mainly active in colon cancer cells at the infiltrative tumor 
edge and is characterized by elevated levels of the transcription factor FRA1 26,38,42. 
1.2.3 The transforming growth factor-β-signaling pathway and the p53 protein  
In addition, anti-proliferative signals that contribute to tissue homeostasis in normal 
tissue, may be deregulated in CRC 43. The transforming growth factor-β 
(TGF-β)-signaling pathway, a major regulator of growth inhibition in epithelial cells, 
can be affected by mutations in SMAD4 11,15,44 (Figure 1). Normally, the SMAD4 
protein transmits TGF-β receptor signaling to the nucleus, which induces expression 
of TGF-β responsive genes 9,43. Mutational inactivation of SMAD4 may disrupt signal 
transduction and facilitates cell proliferation and malignant progression of CRC 14,15.  
Besides promotion of growth, colon cancer cells acquire the ability to evade 
programmed cell death, also referred to as apoptosis 9. One of the main mechanisms 
is the functional inactivation of p53 proteins, which is a result of mutations in the 
tumor suppressor gene TP53 9,45 (Figure 1). The p53 protein is a key sensor of DNA 
damage and induces cell apoptosis upon genomic abnormalities 4,9,45. Loss of p53 
function mediates resistance towards apoptosis and therefore may facilitate 
continued growth of mutated colon cancer cells. Furthermore, inactivation of p53 
protein may promote the acquisition of invasive characteristics enabling tumor cells to 
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detach from the primary tumor mass and to migrate to distant sites in the body, which 
is the basis for metastases formation 4,9.  
1.2.4 The NOTCH pathway 
Also, the NOTCH signaling pathway is highly active in CRC and appears to contribute 
to tumor progression. However, in contrast to other signaling pathways, mutations in 
NOTCH genes are rarely present 46–48. Basically, the canonical NOTCH signaling 
cascade is an evolutionarily conserved pathway that plays crucial roles in embryonic 
development, cell fate decisions, and tissue homeostasis 49–51. This pathway involves 
NOTCH receptors as well as two groups of NOTCH ligands termed Delta-like ligands 
and Jagged ligands, which are located on neighboring cells 21,46,52. NOTCH signaling 
is activated by cell-to-cell contact, mediating the interaction of the NOTCH receptors 
extracellular ligand-binding domains to their ligands 53–55 (Figure 4).  
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Figure 4. The canonical NOTCH signaling pathway. 
NOTCH signaling is activated by the interaction of the NOTCH receptor extracellular ligand-binding domain to its 
ligand, inducing proteolytic cleavages of the NOTCH receptor. The extracellular domain is cleaved off by an ADAM (a 
disintegrin and metalloproteinase) family protease. Cleavage by a γ-secretase complex then results in the release of 
the active NOTCH intracellular domain (NICD) and its translocation to the nucleus. There, NICD complexes with the 
transcription factor recombination-signal-binding protein for immunoglobulin-κ J region (RBPJ) followed by the 
recruitment of Mastermind-like protein 1 (MAML1) and further co-activators. This activation complex induces NOTCH 
target-gene transcription. NICD activity is terminated by ubiquitin-mediated protein degradation. Figure was adapted 
from reference 
56
.  
Ligand binding induces two consecutive proteolytic cleavages of the NOTCH 
receptor 49,52,57. First, an ADAM (a disintegrin and metalloproteinase) family protease 
catalyzes the removal of the NOTCH extracellular domain 57,58. The second cleavage 
by a γ-secretase complex then releases the active NOTCH intracellular domain 
(NICD) into the cytoplasm 53,59,60 (Figure 4). Following this, NICD translocates to the 
nucleus and complexes with the transcription factor recombination-signal-binding 
protein for immunoglobulin-κ J region (RBPJ) that is bound to the promoter of 
NOTCH target genes 46,56,61. Upon NICD-RBPJ binding, the transcriptional-repressor 
complex is converted into an activation complex followed by the recruitment of 
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Mastermind-like protein 1 (MAML1) and further co-activators 54,61,62 (Figure 4). 
Consequently, the transcription of NOTCH target genes is activated. Among those, 
genes encoding members of the Hairy Enhancer of Split (HES) family such as HES1 
are the most common ones 21,46. NOTCH signaling activity is terminated by 
ubiquitin-mediated protein degradation of NICD 54,56 (Figure 4).  
In CRC, the NOTCH signaling pathway is often hyperactive, which is thought to be 
caused by aberrant expression of NOTCH ligands such as JAGGED1 and mutations 
in negative regulators of the NOTCH pathway 46,54. Active NOTCH signaling seems to 
affect a number of tumor-promoting functions in CRC. Intestinal tumor initiation, for 
example, requires active NOTCH signaling mediated by increased levels of 
JAGGED1 63–65. High NOTCH activity has also been linked to cancer stem cell 
phenotypes 66,67 and to EMT 68,69, both contributing to the function of NOTCH 
signaling in tumor progression 70,71. However, contradictory findings also were 
reported and suggested that NOTCH activity represses the expression of WNT target 
genes in human colorectal cancer cells 72. Furthermore, the intratumoral distribution 
of NOTCH activity and associations with distinct tumor cell phenotypes yet are poorly 
characterized. The exact role of the NOTCH pathway in CRC therefore requires 
further elucidation.  
In summary, several signaling pathways are deregulated in CRC, often through 
mutations in pathway components. However, most signaling pathways appear to be 
heterogeneously activated within these tumors, despite the presence of identical 
driver mutations within all tumor cells of a CRC 22,24,26. This may be linked to the 
occurrence of different colon cancer cell phenotypes, which include tumor cells 
undergoing epithelial-mesenchymal transition (EMT) and colon cancer stem cells.  
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1.3 Epithelial-mesenchymal transition 
Activation of invasion and metastasis is one of the hallmarks of cancer and is 
regulated by a molecular and cellular program termed EMT 16. Besides its 
physiological involvement in organ development and wound healing, EMT plays a 
role in tissue fibrosis and cancer progression 73. During EMT, cancer cells undergo a 
phenotypic shift from an epithelial to a mesenchymal state that is characterized by 
loss of cell-cell adhesion and apical-basal polarity, changes in cell shape towards 
spindle-like morphology, and acquisition of motility and invasive features 74–77. In the 
context of tumor progression, cancer cells with activated EMT are able to detach from 
the primary tumor mass, invade surrounding tissues, and may enter the systemic 
circulation 75,77 (Figure 5, a and b). 
 
Figure 5. EMT program activation during carcinoma progression. 
(a) Activation of EMT enables cancer cells to detach from the primary tumor, invade the surrounding tissue and 
intravasate. (b) EMT is maintained in cancer cells within circulation. (c) Following extravasation, cancer cells undergo 
mesenchymal-epithelial transition (MET), the reversal of EMT, to colonize distant tissue and form macroscopic 
metastases. Figure and figure legend were adapted from reference 
77
.  
Following transportation to distant sites, cancer cells with maintained mesenchymal 
phenotype extravasate to the tissue parenchyma 77. However, to colonize these 
tissues and form macroscopic metastases, cancer cells may return to an epithelial 
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state by a reverse process termed mesenchymal-epithelial transition (MET) 77–79 
(Figure 5 c). The reversibility of the EMT program, including EMT as well as MET, 
implies substantial phenotypic plasticity of cancer cells. Findings suggest that this 
plasticity contributes to metastasis formation and is discussed as a possible 
mechanism for evading cancer therapy 77,80.  
The phenotypic shift of colon cancer cells during EMT is based on a number of 
molecular changes. The loss of E-cadherin as the main adherens junction protein in 
epithelia represents a crucial step in the initiation of the mesenchymal state 74,75,81. To 
further stabilize this phenotype, mesenchymal markers such as Fibronectin and 
Vimentin are upregulated 73,77. The shift from epithelial to mesenchymal states is 
mediated by EMT-inducing transcription factors, such as SNAI1, SNAI2, ZEB1 and 
ZEB2, that activate or repress the transcription of EMT-associated genes 73,77,82. The 
CDH1 gene encoding E-cadherin is a key transcriptional target of these EMT 
regulators 16,73,75, which directly bind to E-box sequences on the promoter of CDH1 
leading to its transcriptional repression 83–88.  
For EMT induction in CRC, these transcription factors are activated by multiple 
signaling pathways 73,76,89. For instance, WNT-signaling activity induces the 
expression of ZEB1 and thus may contribute to EMT and the resulting invasive 
phenotype of colon cancer cells 90. Further studies suggest that MAPK signaling 
activity also contributes to EMT by increasing the levels of FRA1 42,73, which directly 
targets EMT-related genes and thus may contribute to the mesenchymal phenotype 
of colon cancer cells as well as to tumor cell plasticity 38,42.  
Within CRC, cancer cells with mesenchymal traits are located predominantly at the 
infiltrative tumor edge, whereas cancer cells towards the center often reveal a more 
epithelial-like phenotype 22,91. The distinct phenotypes of colon cancer cells can be 
assessed by the expression of phenotypic markers. One such marker is the 
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WNT-target LAMC2, which is mainly expressed in invading colon cancer cells at the 
tumor edge and indicates EMT 90–92. Additionally, the expression of the epithelial 
marker E-cadherin is reduced in those cells in contrast to cancer cells in the tumor 
center 26,77. 
To sum up, the EMT program is a major regulator of invasive cancer growth and 
metastasis formation. Due to its implied contribution to phenotypic plasticity of colon 
cancer cells, therapeutic targeting of the EMT program may be a promising approach 
for the development and improvement of cancer treatment. 
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1.4 Colorectal cancer stem cells 
The distinct colon cancer cell phenotypes within CRC further comprise cancer cells 
with stem-like properties, which are defined as cancer stem cells (CSCs) 74. In 
addition to the abilities of self-renewal and tumor initiation, these cells were 
suggested to be capable of differentiating into less-tumorigenic cancer cells forming 
the tumor mass 77,93,94. In solid tumors, CSCs are thought to represent a relatively 
small tumor cell subpopulation that together with the more differentiated progeny cells 
contributes to intratumoral phenotypic heterogeneity 76,77,95,96.  
In CRC, putative CSCs were identified by different cell markers, such as CD133, 
nuclear β-catenin, and leucine-rich repeat-containing G protein-coupled receptor 5 
(LGR5) 97–99. Furthermore, colorectal CSCs seem to be located at the infiltrative 
tumor edge, whereas more differentiated tumor cells are found in the tumor 
center 24,91. To characterize cancer stem cells within tumors, lineage tracing 
approaches were recently developed 100,101. These approaches genetically labeled 
single tumor cells, e.g. by a fluorescent dye. By transmitting this genetic, fluorescent 
label to all progeny cells, expanding clones of tumor cells formed and cells originating 
from a single tumor cell could be identified 102. Using a lineage tracing approach, 
Schepers et al. identified LGR5 expressing colon cancer cells as a cell 
subpopulation, driving intestinal tumor progression 100. The capability of specific 
cancer cells to differentiate into phenotypically distinct tumor cell subpopulations may 
confirm the existence of colorectal CSCs 94,98–100. Further findings suggest that 
less-tumorigenic epithelial cancer cells have the ability to dedifferentiate into 
colorectal CSCs. This implies a plasticity between those cancer cell 
subpopulations 103,104. Moreover, the EMT program mentioned above appears to be 
closely linked to cancer stem cell phenotypes, as the activation of EMT may increase 
stem-like properties of cancer cells 105,106.  
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Tumor cell subpopulations with EMT and CSC phenotypes may have clinical 
importance due to their potential resistance against standard chemotherapy that 
appears to mainly target proliferating cancer cells of the more differentiated tumor 
mass 77,91,95,107. Targeted therapies against such tumor cell subpopulations with high 
activities of oncogenic signaling pathways thus may be a promising approach to 
increase the efficacy of anticancer therapy and to improve personalized medicine in 
CRC. 
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1.5 Treatment of colorectal cancer 
1.5.1 Surgery and chemotherapy 
In early stages of CRC, the complete surgical removal of the tumor may be 
curative 108, whereas the treatment of advanced disease additionally relies on 
systemic therapy. Adjuvant chemotherapy improves patients’ survival rates and is the 
clinical standard treatment of advanced CRC 108–110. When surgery and adjuvant 
chemotherapy become insufficient 68, the use of biologically active agents that target 
oncogenic signaling pathways, such as MAPK and NOTCH signaling, may be 
another treatment option in patients with advanced CRC 68,111. 
1.5.2 Targeted therapy against oncogenic signaling pathways 
Owing to the frequent activation of MAPK signaling in cancer and its contribution to 
tumor progression, targeting MAPK signaling by blocking EGFR with therapeutic 
antibodies such as cetuximab is a commonly used approach 74,112,113. In human CRC 
cell lines, cetuximab only inhibits MAPK signaling in cells without KRAS mutations 114. 
Furthermore, colorectal cancers often develop resistance to cetuximab therapy, 
which is associated with acquired KRAS mutations 115. In the clinical setting, 
treatment with cetuximab improves overall and progression-free survival of patients, 
whereas the therapeutic success is restricted to KRAS wild-type CRC 114,116–118. As 
KRAS mutations are highly frequent in CRC and are associated with poor survival in 
patients with advanced CRC 26,119,120, therapeutic regimens for KRAS mutated CRC 
are of great demand 121. A potential KRAS downstream target may be MEK, which 
can be inhibited by the use of MEK inhibitors 27,36,122. Selumetinib (AZD6244) is a 
potent and selective MEK inhibitor with antitumor activity that has the ability to 
prevent ERK phosphorylation regardless of the KRAS mutation status 28,114,122. 
Furthermore, selumetinib is clinically evaluated. To date, treatment of advanced CRC 
INTRODUCTION 
   16 
 
with selumetinib as single agent prolongs stable disease, however, these beneficial 
effects are limited 123,124.  
Besides targeting MAPK signaling, the NOTCH pathway might be a promising 
therapeutic target due to its aberrant activation and its predominant tumor-promoting 
functions. The most common agents are γ-secretase inhibitors such as 
dibenzazepine (DBZ), which block the γ-secretase-mediated proteolytic cleavage of 
the NOTCH receptor and thus prevent the release of NICD 49,54. In preclinical studies, 
single γ-secretase inhibitor treatment reduced colon cancer cell proliferation, tumor 
formation as well as tumor growth 125,126. By contrast, other studies demonstrated no 
beneficial effects of single agent treatment, whereas the combination of γ-secretase 
inhibitors and chemotherapy increased the treatment response of colon cancer 
cells 127,128. In CRC patients, NOTCH1 positivity as well as high levels of HES1 are 
both associated with poor prognosis 129,130. Several γ-secretase inhibitors are 
currently under clinical evaluation and reveal a downregulation of NOTCH target 
genes in patients with advanced solid tumors 131,132. Regarding antitumor efficacy, 
however, single agent treatment with γ-secretase inhibitors was not beneficial for 
patients with in advanced colon cancers 133,134.  
Despite promising results in preclinical studies 114,125, no benefits of single agent 
treatment with MEK or γ-secretase inhibitors were obtained in the clinical setting, 
respectively 123,133. Therefore further research is needed to identify patients that might 
benefit from targeted therapeutic approaches against active NOTCH and MAPK 
signaling in CRC. 
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2 AIMS OF THE STUDY 
The present study had the following aims: 
 Characterizing NOTCH-signaling activity in colorectal cancer to reveal its 
intratumoral distribution and associated tumor cell phenotypes 
 
 Evaluating the clinical relevance of tumor cell subpopulations with differential 
MAPK and NOTCH signaling activity in colorectal cancer 
 
 Determining phenotypic plasticity of colorectal cancer cells with differential 
phenotypes and pathway activities  
 
 Testing the effects of targeted therapy on tumor cell subpopulations with high 
MAPK or NOTCH pathway activity, and evaluating related changes on tumor 
cell phenotypes and tumor growth 
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3 MATERIALS 
3.1 Chemicals and reagents 
Reagent Supplier 
4-Hydroxytamoxifen ≥70% Z isomer Sigma-Aldrich, St. Louis, MO, USA 
4x Laemmli Sample Buffer Bio-Rad, Munich, Germany 
Acetic acid 100 % Carl Roth GmbH, Karlsruhe, Germany 
Agarose Biozym LE Biozym Scientific, Hessisch Oldenforf, Germany 
Albumin Fraction V Carl Roth GmbH, Karlsruhe, Germany 
All-purpose Hi-Lo DNA Marker Bionexus Inc., Oakland, CA, USA 
Ammonium peroxodisulfate Carl Roth GmbH, Karlsruhe, Germany 
Ammonium sulphate Carl Roth GmbH, Karlsruhe, Germany 
Ampicillin sodium salt Sigma-Aldrich, St. Louis, MO, USA 
Antibody diluent Agilent, Santa Clara, CA, USA 
β-Mercaptoethanol Bio-Rad, Munich, Germany 
Aqua ad iniectablia Deltamedica GmbH, Reutlingen; Germany 
Biofreeze freezing medium Biochrom, Berlin, Germany 
Blasticidin Carl Roth GmbH, Karlsruhe, Germany 
cOmplete™, Mini Protease Inhibitor Cocktail Roche Diagnostics GmbH, Penzberg, Germany 
DAPI (4′,6-Diamidin-2-phenylindol) Carl Roth GmbH, Karlsruhe, Germany 
Deoxycholic acid sodium salt Carl Roth GmbH, Karlsruhe, Germany 
Dibenzazepine  Axon Medchem BV, Groningen, The Netherlands  
Dimethylsulfoxide Carl Roth GmbH, Karlsruhe, Germany 
dNTP Mix Thermo Fisher Scientific Inc., Waltham, MA, USA 
DMEM Biochrom, Berlin, Germany 
Doxycycline hyclate Sigma-Aldrich, St. Louis, MO, USA 
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Reagent Supplier 
Ethylenediaminetetraacetic acid Sigma-Aldrich, St. Louis, MO, USA 
EGF Recombinant Human Protein Thermo Fisher Scientific Inc., Waltham, MA, USA 
Ethidium bromide solution 1% Carl Roth GmbH, Karlsruhe, Germany 
Fetal Bovine Serum  Biochrom, Berlin, Germany 
FGF-Basic (AA 10-155) Recombinant Human 
Protein 
Thermo Fisher Scientific Inc., Waltham, MA, USA 
Glycine Carl Roth GmbH, Karlsruhe, Germany 
imMedia™ Growth Medium, agar, ampicillin Thermo Fisher Scientific Inc., Waltham, MA, USA 
Immobilon-P PVDF Membrane Merck Millipore, Billerica, MA, USA 
Immobilon Western Chemiluminescent HRP 
Substrate 
Merck Millipore, Billerica, MA, USA 
LB Broth (Luria/Miller) Carl Roth GmbH, Karlsruhe, Germany 
Lenti-X Concentrator Clontech, Mountain View, CA, USA 
LipoD293 DNA (Ver. II) Tebu-bio, Le Perray-en-Yvelines, France 
Matrigel Corning Life Sciences, Tewksbury, MA, USA 
Magnesium chloride Qiagen GmbH, Hilden, Germany 
Methanol Carl Roth GmbH, Karlsruhe, Germany 
Methocel (Hydroxypropylmethyl cellulose) Sigma-Aldrich, St. Louis, MO, USA 
Nonidet™ P 40 Substitute Sigma-Aldrich, St. Louis, MO, USA 
PageRuler™ Plus Prestained Protein Ladder Thermo Fisher Scientific Inc., Waltham, MA, USA 
Penicillin/Streptomycin Biochrom, Berlin, Germany 
PhosSTOP™ Roche Diagnostics GmbH, Penzberg, Germany 
Polybrene (Hexadimethrine bromide) Sigma-Aldrich, St. Louis, MO, USA 
ProLong™ Gold Antifade Mountant Thermo Fisher Scientific Inc., Waltham, MA, USA 
Protein Block Agilent, Santa Clara, CA, USA 
Puromycin dihydrochloride Merck Millipore, Billerica, MA, USA 
QIAzol Lysis Reagent Qiagen GmbH, Hilden, Germany 
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Reagent Supplier 
Rotiphorese® Gel 30 (37,5:1) Carl Roth GmbH, Karlsruhe, Germany 
SDS ultra pure Carl Roth GmbH, Karlsruhe, Germany 
Selumetinib (AZD6244) Selleckchem, Houston, TX, USA 
Skim milk powder Sigma-Aldrich, St. Louis, MO, USA 
Sodium chloride Carl Roth GmbH, Karlsruhe, Germany 
Streptavidin, Alexa Fluor™ 488 Thermo Fisher Scientific Inc., Waltham, MA, USA 
Sunflower seed oil from Helianthus annuus Sigma-Aldrich, St. Louis, MO, USA 
Tamoxifen Sigma-Aldrich, St. Louis, MO, USA 
Target Retrieval Solution, Citrate pH 6 Agilent, Santa Clara, CA, USA 
TEMED Carl Roth GmbH, Karlsruhe, Germany 
TRIS Carl Roth GmbH, Karlsruhe, Germany 
TRIS hydrochloride Carl Roth GmbH, Karlsruhe, Germany 
Triton® X 100 Carl Roth GmbH, Karlsruhe, Germany 
TWEEN® 20 Sigma-Aldrich, St. Louis, MO, USA 
TWEEN® 80 Sigma-Aldrich, St. Louis, MO, USA 
 
3.2 Enzymes 
Enzymes Supplier 
FastAP Thermosensitive Alkaline Phosphatase Thermo Fisher Scientific Inc., Waltham, MA, USA 
HotStarTaq DNA Polymerase Qiagen GmbH, Hilden, Germany 
Klenow Fragment Thermo Fisher Scientific Inc., Waltham, MA, USA 
Restriction endonucleases Thermo Fisher Scientific Inc., Waltham, MA, USA 
T4 DNA Ligase Thermo Fisher Scientific Inc., Waltham, MA, USA 
Trypsin/ EDTA solution (0.05 %/0.02 %) Biochrom, Berlin, Germany 
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3.3 Kits 
Kits Supplier 
DC™ Protein Assay Bio-Rad, Munich, Germany 
ImmPRESS™ HRP Anti-Rabbit IgG (Peroxidase) 
Polymer Detection Kit 
Vector Laboratories Inc., Burlingame, CA, USA 
Liquid DAB+ Substrate Chromogen System Agilent, Santa Clara, CA, USA 
mi-Plasmid Miniprep Kit Metabion International AG, Planegg, Germany 
OptiView DAB IHC Detection Kit Ventana Medical Systems, Inc., Tucson, AZ, USA 
Permanent AP Red Kit Zytomed Systems GmbH, Berlin, Germany 
PureYield™ Plasmid Midiprep System Promega GmbH, Mannheim, Germany 
QIAamp DNA Micro Kit Qiagen GmbH, Hilden, Germany 
Quick Start Bovine Serum Albumin Standard Set Bio-Rad, Munich, Germany 
Rapid DNA Ligation Kit Thermo Fisher Scientific Inc., Waltham, MA, USA 
SENSE mRNA-Seq Library Prep Kit Lexogen GmbH, Vienna, Austria 
StemPro™ hESC SFM Thermo Fisher Scientific Inc., Waltham, MA, USA 
TSA Plus Cyanine 3 System Perkin Elmer; Waltham; MA, USA 
UltraView Universal DAB Detection Kit Ventana Medical Systems, Inc., Tucson, AZ, USA 
Wizard® SV Gel and PCR Clean-Up System Promega GmbH, Mannheim, Germany 
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3.4 Oligonucleotides and vectors 
3.4.1 Oligonucleotides 
Name Sequence (5’- 3’) Application 
EGFP rev CGTCGCCGTCCAGCTCGACCAG Sequencing 
KRAS fwd NNNGGCCTGCTGAAAATGACTGAA PCR, sequencing 
KRAS rev Biotin-TTAGCTGTATCGTCAAGGCACTCT PCR 
KRAS exon 2 rev TGTGGTAGTTGGAGCT Sequencing 
mCherry rev GGATGTCCCAGGCGAAGG Sequencing 
WPRE rev GGGCCACAACTCCTCATAAA Sequencing 
Polymerase chain reaction (PCR). reverse (rev), forward (fwd) 
 
3.4.2 Vectors 
Name Insert Reference 
pcDNA3.1 EYFP-V5 EYFP-V5 
135
 
pCMV-dR8.91 Gag-Pol 
136
 
pLenti rtTA3G Reverse tetracycline transactivator 3G Dominic Esposito 
pLenti TetO-CreERT2, CreERT2 
135
 
pLenti Trace mCherry-FLAG, EYFP-V5 This work 
pMD2.G VSV G 
137
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3.5 Antibodies 
3.5.1 Primary antibodies 
Antibody Species/ Clone Order # Supplier WB IF IHC 
BrdU  Mouse/ IIB5 sc-32323 Santa Cruz  1:100  
β-catenin Mouse 610154 BD Biosciences  1:200  
Cleaved Caspase-3 
(Asp175) 
Rabbit/ 5A1E 9664 Cell Signaling   1:100 
Cleaved Notch1 
(Val1744) 
Rabbit/ D3B8 4147 Cell Signaling  1:100 1:100 
E-cadherin Mouse/ G-10 sc-8426 Santa Cruz  1:50 1:200 
E-cadherin Rabbit/ 24E10 3195 Cell Signaling 1:1000   
FRA1 Mouse/ C-12 sc-28310   1:50 1:50 
GFP Mouse/ 4B10 2955 Cell Signaling  1:100  
GFP Rabbit 2555 Cell Signaling  1:100  
HES1 Rabbit/ D6P2U 11988 Cell Signaling 1:1000  1:50 
Ki67 Mouse/ MIB-1 M7240 Agilent   1:150 
Ki67 Rabbit/ D2H10 9027 Cell Signaling  1:100  
Laminin-5-γ2 Mouse/ D4B5 MAB19562 Merck Millipore  1:200  
Phospho p44/42 
MAPK 
(Thr202/Tyr204) 
Rabbit 9101 Cell Signaling 1:1000   
Tubulin Mouse/ DM1A T6199 Sigma-Aldrich 1:50000   
Vimentin Mouse/ V9 M0725 Agilent   1:150 
Immunoblotting (WB), immunofluorescence (IF), immunohistochemistry (IHC) 
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3.5.2 Secondary antibodies 
Antibody Species Application Supplier 
Anti-Mouse AP Polymer - IHC Zytomed Systems GmbH 
Anti-Mouse Biotin Goat IF Thermo Fisher Scientific Inc. 
Anti-Mouse HRP  Goat WB Promega GmbH 
Anti-Rabbit Biotin Goat IF Thermo Fisher Scientific Inc. 
Anti-Rabbit HRP Goat WB Sigma-Aldrich 
Immunoblotting (WB), immunofluorescence (IF), immunohistochemistry (IHC) 
 
3.6 Buffers and solutions 
4x Lower gel buffer 
 0.4 % SDS 
 1.5 M TRIS, pH 8.8 
4x Upper gel buffer 
 0.4 % SDS 
 500 mM TRIS, pH 6.8 
10x PCR buffer 
 100 mM β-Mercaptoethanol 
 67 mM MgCl2 
 166 mM Ammonium sulphate 
 670 mM TRIS, pH 8.8 
10x Running buffer 
 1.92 M Glycine 
 1 % SDS 
 250 TRIS, pH 8.5 
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10x TBS buffer 
 150 mM NaCl 
 20 mM TRIS, pH 7.6 
1x TBST buffer 
 10x TBS buffer 
 0.1 % Tween 20 
10x Transfer buffer 
 1.92 M Glycine 
 20 % Methanol 
 1 % SDS 
 250 mM TRIS, pH 8.5 
50x TAE buffer 
 20 mM Acetic acid 
 1 mM EDTA 
 40 mM TRIS, pH 8.0 
Annealing buffer 
 1 mM EDTA 
 50 mM NaCl 
 10 mM TRIS, pH 7.5- 8.0 
AZD solvent 
 Aqua ad iniectablia 
 0.5 % Methocel 
 0.2 % Tween 80 
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DBZ solvent 
 Aqua ad iniectablia 
 0.5 % Methocel 
 0.1 % Tween 80 
RIPA buffer 
 1 % NP 40 
 150 mM NaCl 
 0.1 % SDS 
 0.5 % Deoxycholic acid sodium salt 
 50 mM TRIS hydrochloride, pH 8.0 
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3.7 Laboratory equipment 
Device Supplier 
Axioplan 2 Carl Zeiss GmbH, Oberkochen, Germany 
BD FACSAria III BD Bioscience, Heidelberg, Germany 
BenchMark XT Ventana Medical Systems, Inc., Tucson, AZ, USA 
Centrifuge 5415R Eppendorf AG, Hamburg, Germany 
Heracell 240i CO2 Incubator Thermo Fisher Scientific Inc., Waltham, MA, USA 
Heraeus Megafuge 40R Centrifuge Thermo Fisher Scientific Inc., Waltham, MA, USA 
Herasafe™ KSP Class II Biological Safety Cabinet Thermo Fisher Scientific Inc., Waltham, MA, USA 
HiSeq 1500 Illumina, Inc., San Diego, CA, USA 
Image Station 440 CF Kodak, Rochester, New York, USA 
Liquid nitrogen cooled mortar Bel-Art – SP Scienceware, Wayne, NJ, USA 
LSM 700 Carl Zeiss GmbH, Oberkochen, Germany 
Mini-PROTEAN Tetra Cell Bio-Rad, Munich, Germany 
MultiImage Light Cabinet Alpha-InnoTec, Kasendorf, Germany 
NanoDrop 1000 Spectrophotometer Thermo Fisher Scientific Inc., Waltham, MA, USA 
Pannoramic DESK II DW 3DHISTECH Ltd., Budapest, Hungary 
PerfectBlue™ 'Semi-Dry'-Blotter, Sedec™ Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
peqPOWER Peqlab Biotechnologie GmbH, Erlangen, 
Germany 
PyroMark Q24 Advanced System Qiagen GmbH, Hilden, Germany 
T100™ Thermal Cycler Bio-Rad, Munich, Germany 
Theromixer comfort Eppendorf AG, Hamburg, Germany 
Varioskan Flash Multimode Reader Thermo Fisher Scientific Inc., Waltham, MA, USA 
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4 METHODS 
4.1 Cloning of pLenti Trace 
All template plasmids were obtained from Addgene (www.addgene.org). For the 
Cre-sensitive recombination vector pLenti Trace, the previously described vector 
pLenti Multicolor 135 was used as template. Its expression cassette containing 
tagged-fluorescent color coding genes and Cre-recombinase recognition sides was 
replaced from Sma1 to Sal1 restriction sites by a synthetic sequence adding loxN 
sites as well as Nru1 and Pml1 restriction sites. Synthetic paired mCherry-FLAG 
(Integrated DNA Technologies, Inc.) then was inserted into the Nru1 site. The second 
tagged-fluorescent color EYFP-V5 was obtained by cleavage of 
pcDNA3.1 EYFP-V5 135 with EcoR1 and Not1 restriction enzymes. To generate blunt 
ends, 5’-overhangs were filled in with Klenow Fragment. Finally, the coding gene of 
EYFP-V5 was inserted into the Pml1 restriction site yielding pLenti Trace. Modified 
vector elements were verified by restriction analysis and Sanger sequencing (GATC 
Biotech AG). 
4.2 Bacterial cell culture  
For cloning procedures and replication of plasmids carrying an ampicillin resistance, 
the Escherichia coli DH5α strain was used. The bacterial cells were cultured 
overnight at 37 °C in LB-medium supplemented with 100 µg/ml ampicillin to select for 
antibiotic-resistant clones. For bacterial transformation, plasmid DNA was added to 
competent E. coli DH5α and incubated for 30 minutes on ice. After a heat-shock for 
45 seconds at 42 °C, the bacteria were placed on ice for two minutes and then 
incubated in 500 µL antibiotic-free LB medium for 45 minutes at 37 °C. Subsequently, 
the bacterial cells were plated on LB agar plates supplemented with ampicillin and 
then incubated overnight at 37 °C. To multiply transformed bacteria, LB medium 
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containing ampicillin was inoculated with a single bacterial colony followed by 
overnight incubation at 37 °C. Depending on the liquid culture volume, plasmid DNA 
was isolated using the mi-Plasmid Miniprep Kit (Metabion International AG) or the 
PureYield™ Plasmid Midiprep System (Promega GmbH) following the manufacturer’s 
protocol. 
4.3 Mammalian cell culture 
4.3.1 Propagation of human cell lines and patient-derived colon cancers 
HEK293 and SW480 cells were obtained from ATCC and SW1222 from the Ludwig 
Institute for Cancer Research (New York, USA). Cell lines were cultured in DMEM 
containing 10 % FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin (Biochrom). To 
establish patient-derived colon cancers, tissue samples of two human primary 
colorectal adenocarcinomas were provided by the biobank under administration of 
the foundation Human Tissue and Cell Research (HTCR) 138. Patient-derived colon 
cancers were cultivated as spheroids in StemPro™ hESC SFM (Thermo Fisher 
Scientific Inc.) supplemented with 20 ng/ml EGF, 10 ng/ml FGF-basic (Thermo Fisher 
Scientific Inc.), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Biochrom) using 
ultra-low attachment cell culture flasks (Corning Life Sciences). All cells were kept in 
a humidified incubator at 37 °C and 5 % CO2. For cryo-preservation, human cell lines 
and patient-derived colon cancers were slowly cooled to -80 °C in cryogenic tubes 
(neoLab Migge GmbH) using 90 % FBS and 10 % DMSO (Carl Roth GmbH) and 
Biofreeze freezing medium (Biochrom), respectively. For long-term storage, cells 
were transferred into liquid nitrogen. 
4.3.2 Lentiviral transductions 
For lentiviral transductions, HEK293 were co-transfected with 10 µg lentiviral vector, 
10 µg pCMV-dR8.91 136 and 3 µg pMD2.G 137 using LipoD293 (Tebu-bio) according to 
the manufacturer’s protocol. Virus containing medium was passed through 0.45 µm 
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filters (Millipore), Lenti-X Concentrator (Clontech) was added and the mixture was 
incubated for 30 minutes at 4 °C. After centrifugation at 1,500 x g for 45 minutes at 
4 °C, the pellet was resuspended in complete DMEM. The virus containing medium 
was used to infect SW480 colon cancer cells in the presence of 8 mg/mL polybrene 
(Sigma-Aldrich). pLenti rtTA3G (kind gift from Dominic Esposito), pLenti TetO-
CreERT2 135, and pLenti Trace triple transduced SW480 cells were selected with 
blasticidin (Carl Roth GmbH) and puromycin (Merck Millipore). Then cells were single 
cell sorted into 96-well plates on a FACSAria III instrument (BD Biosciences) and 
expanded. Recombination was tested in vitro by addition of 0.5 μg/ml doxycycline 
and 1 μM 4-hydroxytamoxifen (Sigma Aldrich), before xenotransplantation into mice. 
4.4 Tumor xenografts and in vivo treatments 
Mouse experiments were reviewed and approved by the Regierung von Oberbayern 
and mice were housed in pathogen free micro-isolator cages. Disaggregated primary 
colon cancers (PDX1 and PDX2), as well as SW1222 or SW480 colon cancer cells 
either native or carrying the lineage tracing constructs, were suspended in 200 μl of a 
1:1 mixture of PBS and growth factor-depleted Matrigel (Corning Life Sciences). This 
mixture then was injected subcutaneously into age- and gender-matched 6-8 week 
old NOD/SCID mice (NOD.CB17-Prkdcscid, The Jackson Laboratory) for xenograft 
formation. Mice were randomly assigned to control or treatment groups when tumor 
volumes reached 100 mm3. For short term therapy and tracing experiments, mice 
were treated daily with 1.25 mg selumetinib (AZD6244, Selleckchem) p.o. or 0.35 mg 
dibenzazepine (DBZ, Axon Medchem BV) i.p. for 5 days. For lineage tracing, 2.5 μg 
doxycycline were given p.o. for 2 days starting on day 3, and recombination of pLenti 
Trace was induced by 7.5 ng tamoxifen i.p. (Sigma Aldrich). For BrdU tracing, mice 
were injected with 1.25 mg BrdU (Sigma Aldrich) 18 hours after last inhibitor 
treatment. For long-term therapy, mice were treated with 1.25 mg AZD and 0.35 mg 
DBZ, or vehicle as control, every 3 days until tumors reached volumes of  
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1,000 –1,300 mm3. Mice were sacrificed, tumors removed, and either formalin fixed 
and paraffin embedded for histology and immunostaining, or directly used for gene 
expression analysis and immunoblotting. 
4.5 Immunoblotting 
For immunoblotting, freshly harvested and snap-frozen tumor samples were ground 
in a liquid nitrogen-cooled mortar (Bel-Art). 60 mg of tissue powder was lysed in RIPA 
buffer supplemented with protease and phosphatase inhibitors (Roche Diagnostics 
GmbH). Samples then were sonicated for 20 seconds, incubated for 30 minutes at 
room temperature and centrifuged at 35,000 x g for another 30 minutes. Protein 
concentrations of the supernatants were measured with the DC Protein Assay 
(Biorad) according to the manufacturer’s protocol using a Varioskan Flash Multimode 
Reader (Thermo Fisher Scientific Inc.). For protein denaturation, 4x Laemmli sample 
buffer (Biorad) was added to 30 µg protein sample and heated for five minutes at 
95 °C. Then samples were loaded on a 10 % SDS polyacrylamide gel and separated 
by electrophoresis at 90-170 V using a Mini-PROTEAN Tetra Cell (Biorad) filled with 
TRIS-glycine-SDS running buffer. Subsequently, proteins were transferred onto 
Immobilon-P PVDF membranes (Merck Millipore) using transfer buffer and the 
PerfectBlue™ 'Semi-Dry'-Blotter, Sedec™ (Peqlab) kept constantly at 100 mA per 
gel. To avoid non-specific antibody binding, membranes were blocked in 5 % skim 
milk/1x TBST for 60 minutes, followed by overnight incubation at 4 °C with primary 
antibodies dissolved in 5 % BSA (Carl Roth GmbH) and 1x TBST. For visualization of 
protein bands, membranes were incubated in horseradish peroxidase 
(HRP)-conjugated secondary mouse (Promega GmbH) or rabbit (Sigma-Aldrich) 
antibodies. Subsequently, a chemiluminescent HRP substrate (Merck Millipore) was 
added and signals were detected using an Image Station 440 CF (Kodak). Primary 
and secondary antibodies used are listed in section 3.5.1 and 3.5.2, respectively. 
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4.6 Histological staining procedures 
4.6.1 Immunohistochemistry 
For immunohistochemistry, 5 µM tissue sections of CRC samples or xenografts were 
deparaffinized and stained on a BenchMark XT autostainer (Ventana Medical 
Systems, Inc.) using primary antibodies as listed in section 3.5.1. Staining was 
visualized with ultraView or optiView DAB detection kits (Ventana Medical Systems, 
Inc.). Immunohistochemical detection of cleaved Caspase-3 and Vimentin was 
performed manually on deparaffinized sections by retrieving antigens in citrate 
(Agilent) for 20 min in a microwave oven followed by incubation with primary 
antibodies. For visualization of cleaved Caspase-3, the ImmPRESS™ HRP 
Anti-Rabbit IgG Polymer Detection Kit (Vector Laboratories Inc.) and the liquid DAB+ 
Substrate Chromogen System (Agilent) were used according to the manufacturer’s 
protocols. Immunostainings of Vimentin were visualized by incubation with alkaline 
phosphatase (AP)-coupled secondary antibodies and AP substrate kits (Zytomed 
Systems GmbH). Primary and secondary antibodies are provided in section 3.5.1 and 
3.5.2, respectively. The intratumoral distribution of NICD and HES1 staining was 
determined by inspection of tumor edge and tumor center in each case. For survival 
analysis, NICD-positive tumor cells were scored in 10 % steps by estimation. FRA1 
expression was scored semi-quantitatively, ranging from complete absence (score 0), 
weak (score 1), moderate (score 2), or strong expression (score 3). Cases then were 
classified as FRA1 negative (score 0) and FRA1 positive (scores 1-3). 
Immunostainings of xenografts were analyzed by counting positive tumor cells or by 
quantification of staining intensities using ImageJ software (NIH).  
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4.6.2 Immunofluorescence 
For double immunofluorescence, a semi-automated protocol was established to 
intensify the staining of weakly detectable proteins. 5 µM tissue sections were 
deparaffinized and stained for primary antibodies on a BenchMark XT autostainer 
(Ventana Medical Systems, Inc.). For signal amplification and visualization, 
Cyanine 3-conjugated tyramide (Perkin Elmer) was used as HRP substrate and 
applied manually. Tissue sections then were incubated in additional primary 
antibodies followed by signal amplification using biotin-labeled secondary mouse or 
rabbit antibodies. Streptavidin-conjugated Alexa Fluor 488 was used for visualization 
and nuclei were counterstained with DAPI (Carl Roth GmbH). Primary and secondary 
antibodies are given in section 3.5.1 and 3.5.2, respectively. A LSM 700 laser 
scanning microscope (Carl Zeiss GmbH) and the ZEN software (Carl Zeiss GmbH) 
were used for taking confocal fluorescence images. Contrast and brightness were 
adjusted in Adobe Photoshop, and for NICD staining a nuclear mask was applied. 
Co-localization of fluorescence signals was quantified using Volocity 6.1.1 software 
(Perkin Elmer) and plotted as percentage values of maximum fluorescence intensity. 
4.7 Gene expression analysis and GSEA 
For RNA isolation, 50 mg of freshly ground tumor samples was further homogenized 
in QIAzol lysis reagent (Qiagen GmbH). Libraries were constructed using the mRNA 
Sense library preparation kit (Lexogen GmbH) according to manufacturer’s protocol. 
In brief, 500 ng of total RNA was captured on oligo dT beads, hybridized to random 
primers and stoppers for cDNA synthesis and ligated. Single stranded cDNAs with 
sequencing adapters then were amplified and barcoded, and libraries were purified 
with AMPure XP beads (Beckman Coulter GmbH), quantified, pooled at 10 nM 
concentration, and sequenced in multiplex on a HiSeq 1500 (Illumina, Inc.) as 50 bp 
single reads. Subsequently, data were demultiplexed, adaptor sequences were 
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removed and the reads were mapped to the hg19 human reference genome. 
Sequence reads for annotated genes were counted with the HTseq count script from 
the DEseq2 package and differentially expressed genes were identified with the 
edgeR package with a <1 % false discovery rate (FDR). Heat maps and clustering 
were done with GENE-E (Broad Institute). Hallmark gene sets 139 most enriched in 
each cluster were determined using Gene Set Enrichment Analysis (GSEA) 
software 140. For enrichment curves, GSEA analyses were run with 
1000 permutations. RNA-seq expression data are accessible through GEO 
(GSE98922). 
4.8 Clinical samples 
CRC specimens from patients that underwent surgical resection at the University of 
Munich between 1994 and 2007 (LMU; Munich) were obtained from the archives of 
the Institute of Pathology. The Munich Cancer Registry recorded the follow-up data 
prospectively. Specimens were anonymized, and the study was approved by the 
institutional ethics committee of the Medical Faculty of the LMU. For the UICC 
stage II collection, inclusion criteria were colorectal adenocarcinomas with bowel wall 
infiltration (T3, T4) but absence of nodal (N0) or distant metastasis (M0) at the time of 
diagnosis. The final collection consisted of 225 cases with 50 events of 
cancer-specific death and 71 events of tumor progression, either documented as 
tumor recurrence or metastasis. For the metastasis collection, a case control design 
was selected, including tumor specimens of 92 patients. Half of the patients had 
colon cancers with synchronous liver metastasis (UICC stage IV), diagnosed by 
clinical imaging or liver biopsy. Colon cancer patients without distant metastasis at 
the time of diagnosis (UICC stages I-III) and with five year disease-free survival after 
primary surgical resection were applied as controls. Cases and controls were 
matched by tumor grade (according to WHO 2010), T-category, and tumor location 
(all tumors were right-sided colon cancers), resulting in 46 matched pairs. 
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Furthermore, 11 paired tissue samples of primary colorectal cancers and their 
metastases to different sites were collected. For KRAS mutational testing, tumor 
tissue was scraped from deparaffinized tissue sections under microscopic control 
using sterile scalpel blades. Tumor DNA was extracted with the QIAamp DNA Micro 
Kits (Qiagen GmbH) following the manufacturer’s protocol. KRAS exon 2 then was 
PCR amplified using the primers KRAS fwd and KRAS rev, and HotStar Taq DNA 
Polymerase (Qiagen GmbH). Subsequently, KRAS exon 2 was analyzed by 
pyrosequencing on the PyroMark Q24 Advanced System (Qiagen) with the primers 
KRAS fwd and KRAS exon 2 rev. Primer sequences are provided in section 3.4.1. 
4.9 Statistical analysis 
Two-tailed Student’s t test was used to evaluate significant differences between two 
groups, and data indicate means ± SD, unless indicated otherwise. For patient 
outcome and mouse survival, the Kaplan-Meier method was used and P-values were 
calculated by the log-rank test. Cox proportional hazards model was used for 
multivariate analysis. Differences were considered statistically significant when 
P < 0.05. Individual P-values are given within the figures. Statistics were calculated 
with GraphPad Prism (GraphPad software, Inc.) or SPSS (IBM). 
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5 RESULTS 
5.1 High NOTCH activity indicates a distinct tumor cell subpopulation in 
colon cancer 
To obtain insights into the role of the NOTCH pathway in CRC, we examined tissue 
specimens of a total of 328 adenocarcinomas for accumulation of NICD, which 
indicates activation of NOTCH signaling. Immunostaining revealed widespread 
nuclear accumulation of NICD in tumor cells of most cases (80.5 %; Figure 6). 
 
Figure 6. Distribution of colorectal cancer cells with high NOTCH activity. 
Representative immunostaining for NICD in primary colon cancer tissue. Right panel shows higher magnification of 
area boxed in the left panel. Arrowheads indicate tumor cells at the tumor edge, and arrows indicate tumor cells 
toward the tumor center; open arrowhead indicates an endothelial cell. Scale bars: 200 μm (left); 20 μm (right). 
Interestingly, however, NICD was not evenly distributed within these tumors. 
Specifically, colon cancer cells that were located at the tumor edge were negative for 
NICD in 89.4 % of these cases, whereas, in contrast, tumor cells located closer to the 
tumor center abruptly became NICD positive (Figure 6). We then examined the 
NOTCH effector HES1 in a subset of 225 cases. Similar to the pattern of NICD, we 
also found expression in the center of colorectal cancers (66.2 %), whereas its 
expression was diminished or absent in tumor cells at the tumor edge (Figure 7). 
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Figure 7. Distribution of HES1 expression in colorectal cancer. 
Representative immunostaining for HES1 in primary colon cancer tissue. Right panel shows higher magnification of 
area boxed in the left panel. Arrowheads indicate tumor cells at the leading tumor edge, and arrows indicate tumor 
cells toward the tumor center; open arrowheads indicate endothelial cells. Scale bars: 200 μm (left); 20 μm (right). 
Collectively, these findings showed that NOTCH signaling is activated in the center of 
colorectal cancers but unexpectedly downregulated at the infiltrative tumor edge. 
Colon cancer cells at the tumor edge are known to activate MAPK and WNT 
signaling 26. Therefore, we compared the activity of both pathways with the status of 
the NOTCH pathway. Using FRA1 and nuclear β-catenin as indicators for MAPK and 
WNT activity, respectively, we found that tumor cells with strong staining for these 
markers showed significantly decreased or absent staining for NICD (Figure 8, A-D). 
 
Figure 8. Comparison of active MAPK and WNT signaling with high NOTCH activity in 
colorectal cancer cells. 
(A and C) Double immunofluorescence for indicated proteins in representative colon cancer tissues. Arrowheads 
indicate tumor cells at the tumor edge, and arrows indicate tumor cells toward the tumor center. Open arrow indicates 
endothelial cells at the tumor edge. Scale bars, 50 µM. (B and D) Quantification of co–immune fluorescence signals. 
Relative fluorescence intensities (% RFI) for indicated proteins in tumor cells with high (upper quartile) and low (lower 
quartile) NICD staining intensity are shown. Data are derived from n ≥ 500 tumor cells in n = 10 different CRC cases. 
Error bars indicate mean ± SD. ***, P < 0.001 by t test. 
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On the contrary, colon cancer cells with high levels of NICD showed much lower 
expression of FRA1 and nuclear β-catenin (Figure 8, A-D). Moreover, tumor cells that 
were positive for NICD on average were more numerous than FRA1-positive tumor 
cells (Figure 9 A). Additionally, NICD-positive tumor cells showed higher proliferation 
rates than tumor cells with FRA1 expression (Figure 9 B).  
 
Figure 9. Characteristics of FRA1- and NICD-positive tumor cells in colorectal cancer. 
(A) Quantification of FRA1- and NICD-positive tumor cells in n = 20 different primary colon cancers. (B) Double 
immunofluorescence (left panels) and quantification of co-immune fluorescence signals (right panel) for Ki67 and 
FRA1 or NICD. Relative fluorescence intensities (% RFI) for Ki67 in individual tumor cells with high (upper quartile) 
FRA1 and NICD staining intensity are shown. Data are derived from n ≥ 500 tumor cells in n = 10 different CRC 
cases. Error bars indicate mean ± SD. ***, P < 0.001 by t test. Scale bars, 50 μm. 
High activities of NOTCH and MAPK/WNT therefore were mutually exclusive in colon 
cancer cells and marked distinct tumor cell subpopulations. Next, we tested for an 
association of NOTCH signaling and EMT. Double immunofluorescence staining 
showed that colon cancer cells with high LAMC2 expression levels, a marker 
indicating EMT in colon cancer 90, were devoid of strong NICD accumulation, 
whereas, in contrast, colon cancer cells with high NICD levels showed low LAMC2 
expression (Figure 10, A and B). 
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Figure 10. Association of NOTCH signaling and EMT phenotype. 
(A and C) Double immunofluorescence for indicated proteins in representative colon cancer tissues. Arrowheads 
indicate tumor cells at the tumor edge, and arrows indicate tumor cells toward the tumor center. Scale bars, 50 µM. 
(B and D) Quantification of co–immune fluorescence signals. Relative fluorescence intensities (% RFI) for indicated 
proteins in tumor cells with high (upper quartile) and low (lower quartile) NICD staining intensity are shown. Data are 
derived from n ≥ 500 tumor cells in n = 10 different CRC cases. Error bars indicate mean ± SD. **, P < 0.01;***, 
P < 0.001 by t test. 
Moreover, colon cancer cells with high NICD levels had significantly higher 
expression of the epithelial cell adhesion molecule E-cadherin, when compared with 
colon cancer cells with low NICD levels (Figure 10, C and D). These findings 
demonstrate that colon cancers are composed of distinct tumor cell subpopulations, 
including tumor cells at the tumor edge with high MAPK and WNT activity undergoing 
EMT and tumor cells with high NOTCH activity in the tumor center that have a more 
epithelial phenotype. 
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5.2 MAPK and NOTCH activity are associated with colon cancer 
progression 
Next, we investigated the clinical relevance of tumor cell subpopulations with high 
MAPK and NOTCH activity by scoring FRA1 and NICD in our collection of CRC 
cases (Figure 11). 225 of these cases were UICC stage II colorectal cancers with 
recorded clinical follow-up data (Table 1).  
 
Figure 11. Scoring of FRA1 and NICD in colorectal cancer. 
Assessment of FRA1 and NICD in primary human colorectal cancers. For FRA1, tumors were categorized as 
negative or positive, based on absence or presence of detectable immunostaining in tumor cells. For NICD, cases 
were categorized as low or high, based on less or more than 10 % tumor cells with strong NICD staining, respectively. 
Scale bars, 50 μm. 
 
Table 1. Clinical data of FRA1 and NICD expression in UICC stage II colorectal cancer. 
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Kaplan-Meier statistics revealed that FRA1-negative cases were associated with a 
tendency toward better cancer-specific and disease-free survival when compared 
with FRA1-positive cases (Figure 12). 
 
Figure 12. Survival analyses of FRA1, NICD, and their combination in colorectal cancer. 
Survival associations of FRA1, NICD, and their combination in 225 UICC stage II colorectal cancers. Kaplan-Meier 
plots for cancer-specific survival and disease-free survival are shown. P-values are log-rank test results. Ratios on 
curves indicate the number of events over the number of patients per group. 
We then tested for associations with NICD staining and found that colorectal cancers 
with <10 % NICD-positive tumor cells (NICD low) also showed significantly better 
cancer-specific and disease-free survival than cases with higher frequencies of 
NICD-positive tumor cells (NICD high; Figure 12). Furthermore, when testing a 
combined evaluation of FRA1 and NICD, we found that patients whose tumors were 
both FRA1 negative and NICD low almost perfectly survived the follow-up period, 
with no event of cancer-specific death and only one event of tumor progression 
(Figure 12). In contrast, patients whose tumors were either FRA1 positive, NICD high, 
or both showed significantly poorer cancer-specific and disease-free survival. Testing 
for associations with other clinical and pathological variables revealed that FRA1 
positivity and high NICD levels were more frequent in low than in high-grade colon 
cancers, whereas the other core clinical variables T-category, age, and sex, as well 
RESULTS 
   42 
 
as KRAS mutation status were not linked to FRA1 or NICD (Table 1). We then 
included these variables into proportional hazards regression analyses and found that 
combined absence of FRA1 and NICD was an independent predictor of favorable 
outcome for disease-free survival (Table 2). 
Table 2. Multivariate analysis of disease-free survival in UICC stage II colorectal cancer. 
 
 
Furthermore, we evaluated 92 colon cancers of a case-control collection of matched 
tumor pairs, with and without synchronous liver metastasis, applying the same 
scoring method as for the UICC II collection (Table 3). 
Table 3. Clinical data of FRA1 and NICD expression in a case-control collection of 
colon cancers with and without distant metastasis. 
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We observed that tumors with liver metastases were significantly more often FRA1 
positive, NICD high, or both, whereas on the contrary, none of the few tumors that 
were FRA1 negative and NICD low had metastasized (Figure 13; Table 3). 
 
Figure 13. Association of FRA1, NICD, and their combination with metastasis in 
colorectal cancer.  
Association of FRA1, NICD, and their combination with liver metastasis in a matched case-control collection of 
92 colon cancers. *, P < 0.05; **, P < 0.01 by χ
2
 test. 
We then also examined another 11 colorectal cancers of which we obtained paired 
tissues of primary tumors and corresponding metastases to the liver (n = 6), the 
peritoneum (n = 3), or the lung (n = 2). Interestingly, nine metastases had 
recapitulated the patterns of FRA1- and NICD-positive tumor cells of their primary 
tumors, whereas only two, in contrast to their primary tumors, showed absent or 
lower FRA1 or NICD staining, respectively (Figure 14). 
 
Figure 14. Distribution of FRA1 and NICD in colon cancer and corresponding liver 
metastasis. 
Representative staining for FRA1 and NICD in a primary colon cancer and corresponding liver metastasis. 
Arrowheads indicate tumor cells at the tumor edge, and arrows indicate tumor cells toward the tumor center; open 
arrowheads indicate endothelial cells. Scale bars, 50 μm. 
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Collectively, these findings suggested that tumor cell subpopulations with MAPK and 
NOTCH activity are both important for colon cancer progression in early- and 
late-stage disease, frequently show similar presence in primary tumors and 
corresponding metastases, and that best clinical outcome may be expected if the 
activity of both pathways is low. 
  
RESULTS 
   45 
 
5.3 Colon cancers evade MAPK- or NOTCH-targeted therapy by shifting 
their phenotype 
MAPK and NOTCH signaling can be repressed with the MEK inhibitor selumetinib 
(AZD) and the γ-secretase inhibitor dibenzazepine (DBZ), respectively. To evaluate 
the effects of either treatment, we used mouse models of cell line-derived SW480 or 
patient-derived PDX1 colon cancer xenografts (Figure 15). 
 
Figure 15. Experimental setup. 
Schema and experimental schedule for xenografting, inhibitor treatment, and tumor analysis. 
Xenograft tumors were composed of tumor cell subpopulations with strong 
expression of FRA1 at the tumor edge, and accumulation of NICD toward the tumor 
center and thus adequately modeled the intratumoral composition and distribution of 
MAPK and NOTCH activity in primary colon cancers (Figure 16 A). 
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Figure 16. Effects of MAPK and NOTCH repression in colon cancer xenografts. 
(A) Immunofluorescence for FRA1 and NICD in SW480 and patient-derived (PDX1) xenografts. Vehicle-treated 
tumors (Ctrl) and AZD- or DBZ-treated tumors at indicated time points were analyzed. Arrowheads indicate tumor 
cells at the tumor edge, and arrows indicate tumor cells toward the tumor center. Areas above dotted lines are tumor 
necrosis. Scale bars, 50 μm. (B and C) Quantification of FRA1- and NICD-positive tumor cells in SW480 and PDX1 
xenografts. Vehicle-treated tumors (Ctrl) and tumors at indicated time points during and after AZD (B) or DBZ (C) 
treatment were analyzed. Error bars are mean ± SD. *, P < 0.05; ***, P < 0.001 by t test; n.s., not significant; 
compared with Ctrl. n ≥ 3 independent biological replicates. 
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We then treated mice bearing these xenografts with AZD for 5 d and observed that 
FRA1 expression was completely lost in these tumors (Figure 16, A and B). Time 
course analysis showed that in SW480 xenografts this already occurred after 2 d of 
treatment (Figure 16 B), which indicated strong and rapid repressive effects of AZD 
on MAPK signaling, as expected. Surprisingly, however, the frequency of 
NICD-positive tumor cells significantly expanded under AZD treatment in SW480 and 
PDX1 xenografts, and these cells then directly reached the tumor edge, suggesting 
an expansion of intratumoral NOTCH activity under MAPK repression (Figure 
16, A and B). In addition, AZD treatment reduced the number of cleaved 
Caspase-3-labeled tumor cells, indicating that the loss of FRA1-positive tumor cells 
was not a result of increased apoptosis (Figure 17, A and B). 
 
Figure 17. Effects of short-term AZD and DBZ treatment on apoptosis in colon cancer 
xenografts. 
(A and B) Representative immunostainings (A) and quantification (B) of cleaved (Cl.) Caspase-3 in SW480 
xenografts. Vehicle-treated tumors (Ctrl) and AZD- or DBZ-treated tumors at indicated time points were analyzed. 
Areas above dotted lines are tumor necrosis. Scale bars, 50 μm. Error bars are mean ± SD. **, P < 0.01; 
***, P < 0.001 by t test; n.s., not significant. n ≥ 3 independent biological replicates. 
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These findings suggest that colon cancer cell subpopulations switched from MAPK to 
NOTCH activity upon MAPK repression. Next, to repress NOTCH signaling, we 
treated SW480 and PDX1 xenografts with DBZ and found complete depletion of 
NICD accumulation in these tumors that in time course analysis in SW480 xenografts 
was fully effective after 3 d of treatment (Figure 16, A and C). However, under DBZ 
treatment, the frequency of FRA1-positive tumor cells significantly increased, 
indicating expanded MAPK signaling upon repression of NOTCH activity (Figure 
16, A and C). Furthermore, in contrast to MAPK inhibition, DBZ treatment significantly 
increased the number of cleaved Caspase-3-labeled tumor cells (Figure 17, A and B), 
suggesting that colon cancer cells with high NOTCH activity were at least in part lost 
from the tumor through apoptosis.  
With these findings in mind, we then analyzed xenograft tumors of mice that had 
been treated with AZD or DBZ and subsequently had been taken off treatment for up 
to 10 d before analysis. Astonishingly, in these tumors the original distributions and 
frequencies of colon cancer cells with FRA1 expression at the tumor edge and NICD 
accumulation in more centrally located tumor cells were readily restored (Figure 
16, A-C). Time course analysis in SW480 xenografts further demonstrated a quicker 
recovery of FRA1-positive tumor cells than of NICD-positive tumor cells from 
respective treatments (Figure 16, B and C). Collectively, these data indicated that 
colon cancers may evade targeted treatment against MAPK or NOTCH signaling by a 
reversible shift in predominating pathway activity. 
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5.4 MAPK and NOTCH have opposite effects on epithelial differentiation in 
colon cancer 
To shed more light on the effects of therapeutic targeting of MAPK and NOTCH 
signaling in colon cancer, we analyzed gene expression in SW480 xenografts after 
AZD or DBZ treatment by RNA-Seq. Considering genes with at least twofold change 
in expression, we found that AZD treatment affected 12.1 % (2,822 genes) of the 
detected transcriptome, whereas DBZ treatment only deregulated 1.9 % (448 genes). 
Differentially expressed genes only partially overlapped, indicating discriminative 
effects of both treatments (Figure 18). 
 
Figure 18. Differential gene expression after AZD and DBZ treatment. 
Venn diagram of genes with significantly (P < 0.05) differential expression and two or more fold change in SW480 
xenografts that were treated for five consecutive days with AZD or DBZ compared with vehicle treatment (Ctrl). n = 3 
independent biological replicates. 
Unsupervised hierarchical clustering of gene expression then revealed four major 
clusters that were characterized by repression (cluster A) or upregulation (cluster D) 
upon AZD treatment or by repression (cluster C) or upregulation (cluster B) upon 
DBZ treatment, respectively (Figure 19). 
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Figure 19. Impact of MAPK and NOTCH repression on gene expression in colon cancer 
in vivo. 
Heat map and unsupervised hierarchical clustering of genes with significantly (P < 0.05) differential expression and 
two or more fold change (left) in SW480 xenografts that were treated for five consecutive days with AZD or DBZ 
compared with vehicle treatment (Ctrl). Rows represent genes and columns represent n = 3 independent biological 
replicates. Four main clusters are indicated. Hallmark gene sets most enriched in each cluster as determined by 
GSEA (right). 
Searching for functional associations, we found that genes, which were repressed by 
AZD treatment (cluster A), were enriched for hallmark gene sets known to be related 
to MAPK activity, such as mTORC1 signaling or MYC-target genes. Surprisingly 
however, when characterizing genes that were upregulated by DBZ treatment 
(cluster B), we found strong enrichment for hallmark gene sets linked to tumor 
progression and, most significantly, to EMT (Figure 19). GSEA analyses on unfiltered 
RNA-Seq data of DBZ-treated xenograft tumors confirmed a highly significantly 
enriched expression of EMT hallmark genes (Figure 20 A). 
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Figure 20. GSEA analyses on DBZ- and AZD-treated colon cancers in vivo. 
(A and B) GSEA for indicated gene sets using unfiltered gene expression data of DBZ- (A) and AZD-treated (B) 
tumors compared with controls. ES, enrichment score; NES, normalized enrichment score. n = 3 independent 
biological replicates. 
On the contrary, when analyzing data from AZD-treated tumors, we found that 
EMT-related genes were strongly repressed (Figure 20 B). At the same time, NOTCH 
repression by DBZ caused overexpression of genes related to KRAS signaling 
(Figure 20 A), whereas MAPK repression with AZD marginally upregulated genes of 
NOTCH signaling (Figure 20 B).  
Because these data suggested opposing effects of MAPK and NOTCH repression on 
EMT, we next looked at individual factors that were linked to EMT in colon cancer. 
ZEB1/2, SNAI1/2, and TWIST, which encode for well-known key EMT regulators, but 
also VIM, which indicates an EMT phenotype, showed significantly higher expression 
levels in DBZ than in AZD treated xenografts (Figure 21 A). 
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Figure 21. Effects of MAPK and NOTCH repression on EMT in colon cancer xenografts. 
(A) Relative expression levels of selected EMT-related genes in SW480 xenografts after 5 d of treatment with AZD or 
DBZ. Data are mean and error bars indicate SD. n = 3 independent biological replicates. (B) Immunoblotting for 
indicated proteins on tumor lysates of SW480 xenografts after 5 d of vehicle (Ctrl), AZD, or DBZ treatment. n ≥ 3 
independent biological replicates, 2 of which are shown. *, P < 0.05; ***, P < 0.001 by t test; n.s., not significant.  
In addition, CDH1, which encodes for E-cadherin and indicates epithelial 
differentiation, was repressed by DBZ and upregulated by AZD. By immunoblotting, 
we confirmed overexpression of E-cadherin upon AZD treatment on the protein level, 
although it was reduced in DBZ-treated tumors (Figure 21 B). Also, immunostaining 
showed strongly increased and expanded E-cadherin expression in tumor cells of 
SW480 and PDX1 xenografts after AZD treatment, whereas, on the contrary, DBZ 
treatment reduced E-cadherin levels in these tumors (Figure 22). 
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Figure 22. Immunostaining of EMT markers in DBZ- and AZD-treated colon cancers 
xenografts. 
Representative immunostainings (left) and quantification of relative staining intensities (% RSI, right) for E-cadherin 
and Vimentin in SW480 and/or PDX1 xenografts after 5 d of vehicle (Ctrl), AZD, or DBZ treatment. Areas above 
dotted lines are tumor necrosis. Scale bars, 25 μm. Error bars are mean ± SD. **, P < 0.01; ***, P < 0.001 by t test; 
n.s., not significant. n ≥ 3 independent biological replicates. 
Furthermore, tumor cells of SW480 xenografts became strongly positive for Vimentin 
after DBZ treatment (Figure 22), whereas PDX1 tumors did not express detectable 
Vimentin levels. Collectively, these data demonstrated that MAPK and NOTCH 
repression had opposing effects on epithelial differentiation in colon cancer, with 
NOTCH repression causing an overall shift toward an EMT phenotype. 
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5.5 Plasticity of MAPK and NOTCH signaling in colon cancer cells 
To further learn about the dynamics of tumor cell subpopulations with active MAPK 
and NOTCH signaling, we developed a lentiviral Cre recombinase–sensitive system 
for lineage tracing in colon cancer xenografts (Figure 23 A). 
 
Figure 23. Lentirviral Cre recombinase-sensitive system for lineage tracing and 
experimental schedule. 
(A) Lentiviral vectors for expression of rtTA (pLenti rtTA3G), doxycycline dependent CreERT2 (pLenti 
TetO-CreERT2), and the Cre-responsive color transgene (pLenti Trace). Upon Cre recombination, the RFP transgene 
element flanked by loxN will be removed, causing an irreversible switch from expression of RFP to YFP fluorescence. 
BlastR/PuroR, blasticid and puromycin resistance genes; LTR, long terminal repeat; PRE posttranscriptional 
regulatory element; TRE, tetracycline response element. (B) Triple transduced colon cancer cells were xenografted 
into NOD/SCID mice. Experimental schedule for Cre recombination by doxycycline (DOX) and tamoxifen (TAM) in 
AZD- or DBZ-treated xenografts. 
This system consists of three lentiviral vectors, two of which mediate doxycycline-
inducible expression of an estrogen receptor Cre fusion protein (pLenti rtTA3G and 
pLenti TetO-CreERT2), and a third vector that upon Cre recombination irreversibly 
switches from expression of RFP to YFP (pLenti Trace). We transduced all three 
vectors into SW480 colon cancer cells and xenografted them into 
immune-compromised NOD/SCID mice. Tumor-bearing mice then were treated with 
AZD or DBZ, causing loss of FRA1- or NICD-positive tumor cell subpopulations, 
respectively. Vehicle-treated tumors were included as controls. During treatment and 
in non-treated controls, recombination was then induced with doxycycline and 
tamoxifen (Figure 23 B). 2 d after recombination, we observed that individual or small 
clusters of tumor cells had been labeled by YFP in all xenograft tumors (Figure 24). 
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Figure 24. Lineage tracing of colon cancer cells after vehicle treatment, and MAPK or 
NOTCH inhibition. 
Representative double immunofluorescence images for YFP, FRA1, and NICD at 2 and 15 d after recombination in 
vehicle-, AZD- and DBZ-treated SW480 xenografts, as indicated. Narrow panels are higher magnifications of areas 
boxed in squared panels. Arrowheads point to FRA1- and NICD-positive tumor cells within single YFP-positive clones 
at 15 d after recombination. Scale bars, 25 μm. 
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Importantly, in AZD-treated tumors, the frequency of NICD-/YFP-double positive 
tumor cells was significantly higher than in non-treated controls, whereas 
FRA1-positive tumor cells were completely absent (Figure 25 A). 
 
Figure 25. Quantification of colon cancer cell-lineage tracing after vehicle treatment, 
and MAPK or NOTCH inhibition. 
(A and B) Quantification of FRA1-/YFP- and NICD-/YFP-double positive tumor cells in vehicle- (Ctrl), AZD-, and 
DBZ-treated SW480 xenografts at 2 d (A) and 15 d (B) after recombination. Error bars are mean ± SD. *, P < 0.05; 
***, P < 0.001 by t test; n.s., not significant. n ≥ 3 independent biological replicates. 
However, DBZ-treated xenografts had higher frequencies of FRA1-/YFP-double 
positive tumor cells than control tumors, but contained no NICD-positive tumor cells 
(Figure 25 A). 15 d after recombination, and after mice had been taken off treatment, 
we found that clonal patches of YFP-positive tumor cells then had formed, which in all 
xenografts included both FRA1- and NICD-positive tumor cell subpopulations (Figure 
24). Importantly, the frequencies of FRA1-/YFP- and NICD-/YFP-double positives 
were then similar to those in non-treated control tumors (Figure 25 B). 
We also treated PDX1 xenograft tumors with AZD or DBZ and then labeled remaining 
NICD- or FRA1-positive tumor cells, respectively, with BrdU (Figure 26). 
RESULTS 
   57 
 
 
Figure 26. Experimental setup for BrdU pulse labeling. 
Schema and experimental schedule for BrdU pulse labeling and chasing in patient-derived PDX1 colon cancer 
xenografts that were treated with AZD or DBZ. 
Analyzing tumors 7 d after AZD or DBZ treatment revealed that the label then had 
expanded to reappeared FRA1- or NICD-positive tumor cells which at the time of 
labeling were absent from the tumor (Figure 27). 
 
Figure 27. BrdU tracing of colon cancer cells after MAPK and NOTCH inhibition. 
Double immunofluorescence for BrdU, FRA1, and NICD at indicated time points after BrdU pulse labeling. 
Arrowheads in right panels point to BrdU staining in reappeared FRA1- and NICD-positive tumor cells at 7 d. Narrow 
panels are higher magnifications of areas boxed in squared panels. Representative data from more than three 
biological replicates are shown. Scale bars, 25 μm.  
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Furthermore, the frequencies of NICD-/BrdU- and FRA1-/BrdU-double positive tumor 
cells in AZD- and DBZ-treated tumors, respectively, were higher at 6 h after labeling 
than at 7 d, where they showed similar frequencies, irrespective of the precedent 
treatment (Figure 28). 
 
Figure 28. Quantification of colon cancer cell BrdU tracing after MAPK and NOTCH 
inhibition. 
Quantification of FRA1-/BrdU- and NICD-/BrdU-double positive tumor cells in AZD- and DBZ-treated SW480 
xenografts at indicated time points after BrdU pulse labeling. Data are mean and error bars indicate SD. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001 by t test; n.s., not significant. n ≥ 3 independent biological replicates. 
Collectively, these findings demonstrate that tumor cell subsets with high MAPK or 
NOTCH activity can be restored from remaining tumor cells during recovery from 
AZD or DBZ treatment and provide evidence for plasticity of signaling pathway 
activity in colon cancer cells. 
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5.6 Treatment effects of MAPK and NOTCH repression in colon cancer 
Finally, we evaluated the effects of targeting MAPK and NOTCH activity on tumor 
growth and survival in colon cancer xenografts. We applied AZD, DBZ, or a 
combination of both at treatment intervals of 3 d for several weeks. In addition to 
SW480 and PDX1, we included cell line-derived SW1222 and patient-derived PDX2 
colon cancer xenografts, both of which also had the distribution of FRA1- and 
NICD-positive tumor cell subpopulations described above. We then evaluated tumor 
growth over time and observed that AZD treatment significantly slowed tumor growth 
of PDX2 tumors only, although it had no significant effects on growth of SW480, 
SW1222, and PDX1 xenografts (Figure 29). 
 
Figure 29. Therapeutic targeting of MAPK and NOTCH in colon cancer xenografts. 
Long-term treatment effects of AZD, DBZ, their combination, or vehicle (Ctrl) on SW480-, SW1222-, and 
patient-derived (PDX1 and PDX2) colon cancer xenografts, shown as growth curves (upper panels) and tumor 
specific survival in Kaplan-Meier plots (lower panels). Data are mean ± SE in growth curves. P-values are log-rank 
test results in Kaplan-Meier plots. n ≥ 10 independent biological replicates for each treatment group. 
Similarly, DBZ treatment slowed tumor growth in PDX2 tumors and also slightly in 
PDX1 tumors, whereas no overall effects on SW480 and SW1222 were observed. 
However, combined treatment with AZD and DBZ significantly slowed tumor growth 
and prolonged tumor-specific survival in all xenograft models, outweighing the effects 
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of single agent treatments (Figure 29). We then examined treated tumors and found 
that double treatments strongly reduced proliferation rates, as indicated by Ki67 
staining, whereas single agent treatments had no significant effects on proliferation 
(Figure 30, A and B). 
 
Figure 30. Impact of long-term MAPK and NOTCH repression on proliferation in colon 
cancer xenografts.  
(A) Quantification of immunostaining for Ki67 proliferation index in long-term treated xenografts with AZD, DBZ, their 
combination, or vehicle (Ctrl). Error bars are mean ± SD. ***, P < 0.001 by t test. n ≥ 3 independent biological 
replicates. (B) Representative immunostainings of Ki67 in SW480-, SW1222-, and patient derived-PDX1 and PDX2 
colon cancer xenografts after indicated long-term treatments. Scale bars, 50 μm. 
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Moreover, double treatment strongly increased apoptosis, as indicated by cleaved 
Caspase-3, whereas single agent treatments again had lower or no significant effects 
(Figure 31, A and B). 
 
Figure 31. Impact of long-term MAPK and NOTCH repression on apoptosis in colon 
cancer xenografts. 
(A) Quantification of immunostaining for cleaved (Cl.) Caspase-3 in in long-term treated xenografts with AZD, DBZ, 
their combination, or vehicle (Ctrl). Error bars are mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by t test. n ≥ 3 
independent biological replicates. (B) Representative immunostainings of cleaved Caspase-3 in SW480-, SW1222-, 
and patient derived-PDX1 and PDX2 colon cancer xenografts after indicated long-term treatments. Scale bars, 
50 μm. 
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All tumors formed areas of tumor necrosis which variably increased upon treatment. 
The most significant increase was seen in SW1222 and PDX2 tumors upon double 
treatment (Figure 32, A and B). 
 
Figure 32. Treatment effects of MAPK and NOTCH repression on necrosis in colon 
cancer xenografts 
(A) Quantification of necrosis in SW480, SW1222, PDX1, and PDX2 colon cancer xenografts after long-term 
treatment with AZD and/or DBZ or vehicle (Ctrl) as indicated. Error bars are mean ± SD. *, P < 0.05; **, P < 0.01; 
***, P < 0.001 by t test; n.s., not significant. n ≥ 3 independent biological replicates. (B) Representative overview 
micrographs of H&E-stained sections of xenograft tumors after indicated long-term treatments. Scale bars, 1 mm.  
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Of note, however, when analyzing double-treated xenograft tumors for FRA1 and 
NICD, we observed some remaining positive tumor cells for both markers, suggesting 
incomplete blockage of MAPK and NOTCH signaling with our treatment protocol 
(Figure 33). 
 
Figure 33. Immunostaining of FRA1 and NICD after long-term double treatment. 
Representative immunostainings for FRA1 and NICD in SW480 xenografts after long-term treatment with vehicle 
(Ctrl), or AZD and DBZ. Arrowheads indicate remaining FRA1- and NICD-positive tumor cells. Scale bars, 25 µm. 
Collectively, these data demonstrate superior therapeutic effects upon combined 
targeting of different tumor cell subpopulations with high MAPK and high NOTCH 
signaling in colon cancer. 
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6 DISCUSSION 
This work demonstrates that in CRC high NOTCH-signaling activity marks tumor cells 
with low levels of MAPK and WNT activity, and vice versa indicating that high 
pathway activities for NOTCH and MAPK/WNT in colon cancer cells are mutually 
exclusive. Additionally, these pathway activities were linked to distinct tumor cell 
phenotypes and thus contribute to intratumoral heterogeneity of colorectal 
cancers 22,26. While tumor cells with high MAPK activity resided at the tumor edge and 
underwent EMT, we found that tumor cells with high NOTCH activity had a 
pronounced epithelial phenotype and were located in the tumor center (Figure 34 A). 
On one hand, these findings can be explained when considering recent data that 
showed a repressive role of NOTCH on MAPK and WNT signaling 72,141, both of 
which are strong inducers of EMT in colon cancer 26,90. On the other hand, our 
findings are unexpected in light of previous studies that suggested induction of EMT 
by NOTCH in various cancer types 68,142–144. However, in contrast to these data that 
were mostly derived from cell culture experiments in vitro or from other tumor entities, 
such as lung or breast cancer, we here assessed the distribution of NOTCH activity in 
primary colon cancer tissues in situ. We therefore suggest that the emergence of 
colon cancer cell subpopulations with full NOTCH activation, their distribution within 
the tumor as well as the associated epithelial phenotype depend on tumor entity and 
require the three-dimensional architecture of growing in vivo. Therapeutic targeting of 
colon cancer cells with high MAPK or NOTCH activity by MEK or γ-secretase 
inhibitors caused a loss of respective tumor cell subpopulations in colon cancer 
xenografts (Figure 34, B and C). 
  
DISCUSSION 
   65 
 
 
Figure 34. Treatment effects of MAPK and NOTCH inhibition on intratumoral 
heterogeneity and EMT in CRC. 
(A) Intratumoral distribution of tumor cells with active MAPK and NOTCH signaling in CRC. Tumor cells with high 
MAPK activity are located at the infiltrative tumor edge and underwent EMT. NOTCH signaling is active in tumor cells 
in the tumor center, revealing epithelial traits. (B) Upon repression of MAPK signaling, using a MEK inhibitor, MAPK 
activity within the tumor is erased, while the NOTCH-active tumor cell subpopulation is expanded. Simultaneously, 
epithelial traits, indicating MET, are increased. (C) Upon NOTCH inhibition, using a γ-secretase inhibitor, tumor cells 
with high MAPK activity were unaffected or even expanded with a concurrent increase in mesenchmymal features, 
indicating EMT.  
Furthermore, we demonstrate that tumor cells with high MAPK activity were 
unaffected or even expanded when targeting NOTCH (Figure 34 C), while the 
NOTCH-active tumor cell population expanded when targeting MAPK signaling 
(Figure 34 B). These shifts in predominating pathway activity were accompanied by 
changes in tumor cell phenotypes. Upon NOTCH repression, gene expression and 
protein levels indicated strongly increased EMT, whereas MAPK repression had 
opposite effects. Since MAPK is a strong driver of EMT in colon cancer 26,145,146, the 
elimination of tumor cell subsets with high MAPK activity may induce the shift towards 
an epithelial phenotype in colon cancer xenografts. Additionally, it was already shown 
in vitro that MEK inhibition as well as FRA1 depletion suppress mesenchymal 
features and induce differentiation in colorectal cancer cells 42,122,147. When further 
considering that EMT is a hallmark of cancer progression 16, we propose that solely 
targeting NOTCH may elicit limited or even adverse effects on the risk of tumor 
progression for patients with colon cancer. Our data therefore imply that single agent 
therapies that target specific signaling pathways require careful evaluation due to 
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unexpected effects on overall tumor cell differentiation. Furthermore, single agent 
therapies may cause transitions into potentially aggressive tumor cell populations 
with intrinsically treatment-resistant phenotypes, often characterized by an 
EMT-associated gene expression profile 77,148.  
Upon recovery from therapy, colon cancer cells with high MAPK or NOTCH activity, 
respectively, were quickly replenished. Using genetic and BrdU lineage tracing, we 
demonstrate clonal outgrowth of MAPK- and NOTCH-positive tumor cells from the 
remaining tumor cell population irrespective of the pathway that was targeted, 
indicating phenotypic plasticity in signaling pathway activity as an underlying 
mechanism for treatment recovery. In line with these findings, a recent study 
demonstrated prompt reappearance of LGR5-positive colon cancer cells after their 
genetic ablation in tumor xenografts, indicating that tumor cell plasticity allowed 
reversion of differentiated tumor cells into colon cancer stem cells 103. In this context, 
it remains to be determined, if colon cancer cells which express LGR5 or other 
putative cancer stem cell markers reside within MAPK- and/or NOTCH-positive tumor 
cell subpopulations. Beside the plasticity between cancer stem cells and 
differentiated tumor cells 103,104, the reversibility of the EMT program might further 
support the phenotypic plasticity between distinct tumor cell subpopulations 77,79. 
Upon MAPK repression, for instance, MAPK-positive tumor cells associated with a 
mesenchymal phenotype may shift into NOTCH-positive tumor cells with epithelial 
features through MET. During recovery from MAPK repression, in turn, the 
reactivation of EMT in the remaining NOTCH-positive tumor cell subpopulation may 
induce the reappearance of MAPK-positive tumor cells. Hence, these data suggest 
that solely targeting colon cancer cell subpopulations with distinct phenotypes, such 
as EMT or enhanced stemness 77, may clinically fail due to plasticity of phenotype 
and signaling pathway activity.  
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Indeed, when we treated colon cancer xenografts for several weeks with MAPK or 
NOTCH inhibitors alone, effects on tumor growth either were non-significant or 
moderate only, which is in line with their limited effects in previous therapeutic 
trials 123,133. However, when combining both therapies, we found strong repressive 
effects on tumor cell proliferation and increased apoptosis, resulting in slowed tumor 
growth and prolonged tumor-specific survival. In melanomas, for instance, similar 
antitumor activities were obtained upon combined repression of NOTCH and MAPK 
signaling 149,150. Given that combinatorial therapies significantly outweighed those of 
single agent treatments, our findings denote that in CRC combined treatments mainly 
succeeded by restricting tumor cell plasticity. Furthermore, therapeutic targeting of 
active EMT in tumors to induce differentiation and epithelial features is discussed as 
a promising strategy in anticancer treatment 74,76,77. By contrast, our data indicate that 
combined inhibition of signaling pathways active in EMT as well as MET phenotypes 
ultimately revealed improved antitumor efficacy. This lends support to a new concept 
for cancer therapy which advocates targeting of intratumoral heterogeneity by 
simultaneous repression of different tumor cell subpopulations to strongly improve 
therapy response. Detailed analyses of targetable phenotypes and pathways found in 
different tumor cell subpopulations may thus pave the way for improved treatment 
options for patients with colorectal and other cancers.  
The contribution of colon cancer cell subpopulations to tumor progression is not yet 
completely understood, however, our data shed useful light on the clinical relevance 
of MAPK and NOTCH activity. Cancer progression requires invasion and 
dissemination of tumor cells, which are strongly driven by EMT 78. However, it also 
requires seeding at metastatic sites which depends on MET 73. Because we 
demonstrate that MAPK and NOTCH activity are linked to EMT and MET 
phenotypes, respectively, both pathways likely foster colon cancer progression in 
concert. This idea finds support in our observation that combined analyses of MAPK 
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and NOTCH activity through FRA1 and NICD was most discriminatory in predicting 
patient outcome and tumor metastasis. Importantly however, since patients whose 
tumors showed low activity for both pathways survived best and showed lowest tumor 
progression and metastasis rates, this further strengthened the rationale for 
combined targeted treatment against both pathways. As immunostainings for FRA1 
and NICD readily indicated presence and extent of respective tumor cell 
subpopulations in colon cancer specimens, and also often were consistent in primary 
colon cancers and their metastases, these may well be evaluated as predictive 
biomarkers. The stratification of CRC patients according to FRA1 and NICD 
expression in future clinical trials, might help to identify patients that benefit from 
combinatorial therapies with MEK and γ-secretase inhibitors 27,49. Consequently, the 
clinical efficacy of targeted therapies against MAPK- and NOTCH-pathway activities 
might be predicted by the use of FRA1 and NICD in biomarker-based 
approaches 27,30,49,151. 
In addition to predictive biomarkers, the classification of CRCs based on gene 
expression profiles may contribute to better clinical stratification 121,152. Recently, four 
consensus molecular subtypes (CMSs) of CRC with different features have been 
proposed. CRCs with subtype CMS2, for instance, reveal epithelial features, whereas 
CSM4 CRCs have a mesenchymal phenotype that is characterized by increased 
expression of EMT-associated genes. Additionally, tumors with mixed features exist, 
possibly indicating intratumoral heterogeneity 152. Moreover, CRCs of the 
mesenchymal CMS4 subtype are associated with poor prognosis and may not 
respond well to adjuvant chemotherapy 148. Hence, colorectal cancers revealing 
active MAPK and NOTCH signaling should be further characterized on gene 
expression levels to determine the CMS subtype 152. Based on our data, MAPK and 
NOTCH signaling are associated with mesenchymal and epithelial traits in CRC, 
respectively. Thus, tumors with heterogeneous MAPK and NOTCH pathway activity 
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might represent a mixed CMS subtype that could be targeted specifically by a 
combinatorial therapeutic approach with MEK inhibitors and γ-secretase inhibitors.  
Hence, we here provide evidence that combined targeting of MAPK and NOTCH 
signaling can improve therapeutic response in preclinical xenograft models of CRC. 
However, this study has certain limitations. Our data are derived from 
immune-compromised animals which partially lack the inflammatory 
microenvironment and tumor-directed immune response, so that treatment effects in 
human patients with CRC may significantly differ. Moreover, since several 
substances for MAPK and NOTCH inhibition are clinically evaluated 49,112, most 
tolerable and effective drug combinations in human patients still remain to be 
determined. Toxic side effects, especially of combined MAPK and NOTCH inhibition 
also need to be thoroughly assessed. Finally, while long-term repression of MAPK 
and NOTCH signaling significantly slowed tumor growth, blockage of both pathways 
was incomplete, and also this treatment failed to regress established tumors. Further 
preclinical and clinical trials may therefore reveal if combined MAPK and NOTCH 
inhibition in addition to established chemotherapeutic protocols can improve therapy 
response in patients with CRC.  
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SUMMARY 
In CRC, signaling pathways driving tumor progression are promising targets for 
systemic therapy. Besides WNT and MAPK signaling that are active in tumor cells at 
the infiltrative tumor edge and associated with EMT, activation of NOTCH signaling is 
found in most tumors. Here we demonstrate that high NOTCH activity marks a 
distinct colon cancer cell subpopulation, which is located in the tumor center and 
shows low levels of WNT and MAPK activity as well as a pronounced epithelial 
phenotype. Therapeutic targeting of MAPK signaling in colon cancer xenografts had 
limited effects on tumor growth, caused expansion of tumor cells with high NOTCH 
activity, and promoted epithelial traits. Upon targeting of NOTCH signaling, on the 
contrary, tumor cells with high MAPK activity and an enhanced EMT phenotype 
prevailed. Lineage tracing experiments indicated high plasticity between both tumor 
cell subpopulations as a mechanism for treatment resistance. Combined targeting of 
NOTCH and MAPK had superior therapeutic effects on colon cancer growth in vivo. 
In CRC case collections, active MAPK and NOTCH signaling was associated with 
tumor progression, whereas their combined evaluation was most discriminatory in 
predicting patient outcome and tumor metastasis. Collectively, these findings provide 
a rationale for combinatorial therapeutic targeting of MAPK and NOTCH signaling in 
CRC. Targeting different tumor cell subpopulations may reduce treatment resistance 
by tumor cell plasticity. 
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ZUSAMMENFASSUNG 
Signalwege, die zur Tumorprogression von Kolonkarzinomen beitragen, gelten als 
vielversprechende Angriffspunkte zielgerichteter Therapieansätze. Eine Vielzahl von 
Tumoren weist neben einer erhöhten Aktivität des WNT und des MAPK Signalwegs, 
eine Überaktivierung des NOTCH Signalweges auf. Der WNT und MAPK Signalweg 
sind in Tumorzellen aktiv, die einen mesenchymalen Phänotyp aufweisen und an der 
Invasionsfront der Tumoren lokalisiert sind. In dieser Arbeit konnte gezeigt werden, 
dass Tumorzellen mit einer erhöhten NOTCH Signalwegaktivität eine niedrige 
Aktivität des WNT und MAPK Signalwegs aufweisen und im Kolonkarzinom eine 
eigene Tumorzellsubpopulation darstellen. Diese ist im Tumorzentrum lokalisiert und 
weist epitheliale Eigenschaften auf. Die Effekte einer zielgerichteten Therapie gegen 
den MAPK Signalweg in Kolonkarzinomxenotransplantaten waren gering und führte 
zu einer Zunahme von Tumorzellen mit erhöhter NOTCH Signalwegaktivität. Bei der 
Inhibierung des NOTCH Signalwegs wiederum, blieben Tumorzellen mit erhöhter 
MAPK Aktivität übrig, die den Phänotypen einer epithelial-mesenchymalen Transition 
zeigten. Mit Hilfe von „Lineage-tracing“ Experimenten konnte gezeigt werden, dass 
beide Tumorzellsubpopulationen plastisch ineinander übergehen können. Eine 
Kombinationstherapie gegen den NOTCH und MAPK Signalweg konnte das 
Wachstum von Kolonkarzinomxenotransplantaten deutlich reduzieren. In 
Patientenkollektiven mit Kolonkarzinomen konnte gezeigt werden, dass MAPK und 
NOTCH Signalwegaktivität, vor allem jedoch die Aktivität beider Signalwege 
kombiniert, mit schlechter Prognose und Metastasierung von Patienten assoziiert 
sind. Aus dieser Arbeit lässt sich daher ein neuer kombinierter Therapieansatz 
ableiten, der sich gegen unterschiedliche Tumorzellsubpopulationen mit hoher MAPK 
und NOTCH Aktivität richtet. Dieses neue Therapiekonzept ermöglicht es offenbar 
Behandlungsresistenzen beim Kolonkarzinom zu umgehen, die durch 
Tumorzellplastizität entstehen können. 
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ABBREVIATIONS 
A ADAM A disintegrin and metalloproteinase 
 AP Alkaline phosphatase 
 AP1 Activator protein 1 
 APC Adenomatous polyposis coli 
 AZD Selumetinib, AZD6244 
B bp Base pair 
 BrdU Bromodeoxyuridine 
 BSA Bovine serum albumin 
C cDNA complementary DNA 
 CMS Consensus molecular subtype 
 CRC Colorectal cancer 
 CSCs Cancer stem cells 
 Ctrl Control 
D DAB 3,3'-Diaminobenzidine 
 DAPI 4′,6-Diamidin-2-phenylindol 
 DBZ Dibenzazepine 
 DMEM Dulbecco's Modified Eagle Medium 
 DMSO Dimethylsulfoxide 
 DNA Deoxyribonucleic acid 
E E. coli Escherichia coli 
 EGF Epidermal growth factor 
 EGFR Epidermal growth factor receptor 
ABBREVIATIONS 
   73 
 
 EMT Epithelial-mesenchymal transition 
 ERK Extracellular signal-regulated kinase 
 ES Enrichment score 
 EYFP Enhanced yellow fluorescent protein 
F FBS Fetal bovine serum 
 FDR False discovery rate 
 FGF Fibroblast growth factor 
 FRA1 FOS-related antigen 1 
 fwd Forward 
G GDP Guanosine diphosphate 
 GEO Gene expression omnibus 
 GFP Green fluorescent protein 
 GRB2 Growth factor receptor-bound protein 2 
 GSEA Gene set enrichment analysis 
 GTP Guanosine triphosphate 
H HES Hairy Enhancer of Split 
 HRP Horseradish peroxidase 
 HTCR Human tissue and cell research 
I i.p. Intraperitoneal 
L LGR5 Leucine-rich repeat-containing G protein-coupled receptor 5 
 LOH Loss of heterozygosity 
M MAML1 Mastermind-like protein 1 
 MAPK Mitogen-activated protein kinase 
 MEK MAPK kinase 
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 MET Mesenchymal-epithelial transition 
N NaCl Sodium chloride 
 NICD NOTCH intracellular domain 
 NES Normalized enrichment score 
 NP40 Nonidet™ P 40 Substitute 
P p.o. Orally 
 PCR Polymerase chain reaction 
 PDX Patient derived xenograft 
R rev Reverse 
 RFI Relative fluorescence intensity 
 RFP Red fluorescent protein 
 RIPA Radioimmunoprecipitation assay 
 RSI Relative staining intensity 
 rtTA3G Reverse tetracycline transactivator 3G 
S SDS Sodium dodecyl sulfate 
 SOS Son of Sevenless 
T TCF4 Transcription factor 4 
 TGF-β Transforming growth factor-β 
U UICC Union international contre le cancer 
V V Volt 
 VSV-G Vesicular stomatitis virus G glyoprotein 
W WPRE Woodchuck hepatitis post-transcriptional regulatory element 
Y YFP Yellow fluorescent protein 
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